



EPA, DHA, and lipoic acid differentially modulate the n-3 fatty acid biosynthetic pathway in Atlantic salmon hepatocytes

Journal:	<i>Lipids</i>
Manuscript ID	LIPIDS-16-0270.R1
Manuscript Type:	Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Bou, Marta; NOFIMA AS, Department of Nutrition and Feed Technology; Norges miljø- og biovitenskapelige universitet, Department of Animal and Aquacultural Sciences ostbye, tone-kari; Nofima AS, Department of Nutrition and Feed Technology Berge, Gerd; Nofima AS, Department of Nutrition and Feed Technology Ruyter, Bente; Nofima AS, Department of Nutrition and Feed Technology; Norges miljø- og biovitenskapelige universitet, Department of Animal and Aquacultural Sciences
Keywords:	Fatty acid metabolism < Metabolism, Fish nutrition < Nutrition, n-3 Fatty acids < Nutrition, Desaturases < Specific Lipids, Elongases < Specific Lipids

1 **EPA, DHA, and lipoic acid differentially modulate the n-3 fatty acid biosynthetic**
2 **pathway in Atlantic salmon hepatocytes**

3 Marta Bou^{1,2}, Tone-Kari Østbye¹, Gerd M. Berge³, Bente Ruyter^{1,2}

4

5 ¹ Nofima (Norwegian Institute of Food, Fisheries and Aquaculture Research), P.O. box 210,
6 N-1432 Ås, Norway

7 ² Department of Animal and Aquacultural Sciences, Norwegian University of Life Sciences,
8 Ås, Norway

9 ³ Nofima, NO-6600 Sunndalsøra, Norway

10

11 *Corresponding author: Marta Bou. Nofima (Norwegian Institute of Food, Fisheries and
12 Aquaculture Research), P.O. Box 210, NO-1431 Ås, Norway. Phone +47 45 86 18 31, Email:
13 marta.bou@nofima.no

14 **ABSTRACT**

15 The aim of the present study was to investigate how EPA, DHA, and lipoic acid (LA)
16 influence the different metabolic steps in the n-3 fatty acid (FA) biosynthetic pathway in
17 hepatocytes from Atlantic salmon fed four dietary levels (0 %, 0.5 %, 1.0 % and 2.0 %) of
18 EPA, DHA or a 1:1 mixture of these FA. The hepatocytes were incubated with [1-¹⁴C] 18:3n-3
19 in the presence or absence of LA (0.2 mM). Increased endogenous levels of EPA and/or
20 DHA and LA exposure both led to similar responses in cells with reduced desaturation
21 and elongation of [1-¹⁴C] 18:3n-3 to 18:4n-3, 20:4n-3, and EPA, in agreement with reduced
22 expression of the $\Delta 6$ desaturase gene involved in the first step of conversion. DHA
23 production, on the other hand, was maintained even in groups with high endogenous levels
24 of DHA, possibly due to a more complex regulation of this last step in the n-3 metabolic
25 pathway. Inhibition of the $\Delta 6$ desaturase pathway led to increased direct elongation to 20:3n-
26 3 by both DHA and LA. Possibly the route by 20:3n-3 and then $\Delta 8$ desaturation to 20:4n-3,
27 bypassing the first $\Delta 6$ desaturase step, can partly explain the maintained or even increased
28 levels of DHA production. LA increased DHA production in the phospholipid fraction of
29 hepatocytes isolated from fish fed 0 % and 0.5 % EPA and/or DHA, indicating that LA has
30 the potential to further increase the production of this health-beneficial FA in fish fed diets
31 with low levels of EPA and/or DHA.

32

33 | **KEYWORDS:** desaturases, elongases, fatty acid metabolism, fish nutrition, *in vitro*, n-3 fatty
34 acids

35 **ABBREVIATIONS**

36

37 | ASP Acid-soluble products

38 | CE Cholesterol esters

39 | DHA Docosahexaenoic acid (22:6n-3)

40 | EPA Eicosapentaenoic acid (20:5n-3)

41 | FO Fish oil

42 | LA Lipoic acid

43 | MDG Monoacylglycerols and diacylglycerols

44 | NL Neutral lipids

45 | PL Phospholipids

46 | PUFA Polyunsaturated fatty acids

47 | TAG Triacylglycerol

48 | VLC-PUFA Very-Long chain polyunsaturated fatty acids

49 | VO Vegetable oil

50 **1. INTRODUCTION**

51 Norwegian farmed Atlantic salmon (*Salmo salar* L) has faced major changes in their feed
 52 composition during the last decades, changing from a purely marine-based diet in the 1990s
 53 to diets containing 70 % plant ingredients [1]. As a result, the levels of health-promoting
 54 omega-3 ~~very~~-long chain polyunsaturated fatty acids (n-3 ~~V~~LC-PUFA) eicosapentaenoic
 55 (EPA; 20:5n-3) and docosahexaenoic (DHA; 22:6n-3) acids decreased significantly in salmon
 56 organs and tissues [2]. Nevertheless, the lipid composition of an organism is not only
 57 affected by ingested lipids, but also by the capacity of organs or tissues to transform these
 58 lipids through desaturation and elongation pathways and by the endogenous capacity to
 59 synthesize lipids. Vertebrates lack the necessary enzymes to produce n-3 LC-PUFA de
 60 novo, and thus their production ~~of VLC-PUFA~~ is dependent on biosynthesis from essential
 61 preformed C₁₈ PUFA obtained from the diet [3].

62 Endogenous production of ~~V~~LC-PUFA differs notably among species, and is determined to a
 63 large extent by the repertoire of fatty acyl elongase (Elovl) and desaturase (Fad) enzymes
 64 and their substrate specificities [4]. Salmonids, including Atlantic salmon, are able to
 65 elongate and desaturate C₁₈ PUFA to C₂₀ and C₂₂ PUFA [5, 6], and knowledge of the key
 66 enzymes involved is available [7-11]. Both bioactive ~~V~~LC-PUFA arachidonic acid (ARA;
 67 20:4n-6) and EPA are synthesized by the same enzymes, requiring a Δ 6 desaturation of
 68 18:2n-6 and α -linolenic (ALA; 18:3n-3) precursors, respectively, followed by chain elongation
 69 and a further Δ 5 desaturation. Alternatively, 20:5n-3EPA can be produced via elongation of
 70 18:3n-3 to 20:3n-3 followed by Δ 8 and Δ 5 desaturation [12, 13]. DHA synthesis from EPA
 71 requires two further elongations, a Δ 6 desaturation and a peroxisomal β -oxidation chain-
 72 shortening step [14]. However, a more direct pathway for DHA production from EPA via
 73 elongation to 22:5n-3 and Δ 4 desaturase has been recently described in several teleost
 74 species [15-19] as well as in humans [20]. There are sSeveral ~~are the~~ factors controlling the
 75 n-3 fatty acid (FA) biosynthetic pathway. Although the same desaturases and elongases
 76 compete for FA substrates of the n-6 and n-3 families, in general with a preference for n-3
 77 [3], the dietary FA ~~dietary~~ composition is known to influence enzyme activity. For instance,
 78 hepatocytes from Atlantic salmon fed diets with high levels of n-6 FA presented a higher
 79 capacity to increase the products of Δ 6-desaturase from 18:3n-3 [21, 22]. In addition, the
 80 desaturation and elongation of 18:2n-6 and 18:3n-3 have been shown to be markedly
 81 enhanced by EFA deficiency [6].

82 Lipid-sensing transcription factors such as sterol regulatory element binding protein 1
 83 (SREBP1) play a role in the transcriptional regulation of ~~V~~LC-PUFA biosynthesis in Atlantic
 84 salmon [23]. The expression of genes of the LC-PUFA biosynthetic pathway (*e/ovl* and

85 *fads2*) is regulated by SREBP1 in salmon, and the *srebp1* gene is transcriptionally activated
86 by diets containing vegetable oils (VO) [23]. VO-based diets have been consistently reported
87 to increase enzymatic activity of desaturases and elongases to produce EPA and DHA from
88 ALA-18:3n-3 [24, 25]. Two explanations have been proposed: no inhibitory effect from dietary
89 VLC-PUFA, or a stimulatory effect from high concentrations of C₁₈ substrates [25-27].
90 Despite the stimulatory effect on the enzymes, FO-based feeds result in higher DHA tissue
91 levels than those obtained with VO-diets [2, 28]. Similar results are observed in mammals, in
92 which 18:3n-3 supplementation increases EPA and DHA levels but to a lower degree than
93 that attained with direct use of the preformed n-3 VLC-PUFA [29]. Thus, a better
94 understanding of FA bioconversion capabilities would allow improved dietary FA utilization in
95 farmed fish, thereby providing a significant contribution towards more efficient use of marine
96 resources in fish feeds.

97 Different strategies to optimize the innate capacities for EPA and DHA production from ALA
98 can be used. For example, the FA composition of the diet may be optimized or a bioactive
99 component to stimulate the pathway may be included. Lipoic acid (LA) is a promising
100 bioactive molecule that plays a role in controlling lipid homeostasis [30]. In addition, LA
101 possesses important antioxidant properties [31]. LA was shown to increase the nutritional
102 value of the South American pacu (*Piaractus mesopotamicus*) by increasing EPA levels in
103 the muscle [32], indicating a role in the regulation of the n-3 pathway.

104 In the present study we aimed to test the hypothesis that both optimized diet composition
105 and use of bioactive components such as LA play an important role in modulating the
106 capacity of Atlantic salmon hepatocytes to produce EPA and DHA from 18:3n-3.

107

108 2. MATERIALS AND METHODS

109 2.1 Chemicals and reagents

110 Radiolabeled FA [¹⁴C] 18:3n-3 (50 mCi/mmol) was obtained from American Radiolabeled
111 Chemicals (St. Louis, MO, USA). α-Lipoic acid (racemic form), essential FA-free bovine
112 serum albumin (BSA), fetal bovine serum (FBS), Leibovitz-15 (L-15), 20,70-
113 dichlorfluorescein, 20,70-dichlorfluorescein, collagenase, phosphate buffer saline (PBS),
114 phenylethylamine, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), BHT,
115 sodium bicarbonate solution, L-glutamine, Trypan blue, antibiotics, and total protein kit were
116 obtained from Sigma-Aldrich (St. Louis, MO, USA). Cell flasks and cell scrapers were
117 obtained from Nalge Nunc International (Rochester, NY, USA). Metacain MS-222 was
118 purchased from Norsk Medisinaldepot (Norway). Perchloric acid (HClO₄), thin-layer

119 chromatography (TLC) plates, and all solvents and other chemicals for FA analysis were
120 purchased from Merck (Darmstadt, Germany). FA peaks were identified by comparison with
121 the standard mixtures GLC-85 and GLC-463 obtained from Nu-chek Prep (Elysian, MN,
122 USA). Ecoscint A scintillation liquid was purchased from National Diagnostics (Atlanta, GA,
123 USA). PureLink Pro 96 RNA Purification Kit and PureLink DNase were obtained from
124 Invitrogen (Carlsbad, CA, USA), TaqMan Reverse Transcription Reagents kit from Applied
125 Biosystems (Foster City, CA, USA), and LightCycler 480 SYBR Green I Master from Roche
126 Applied Science (Mannheim, Germany).

127 2.2 Fish and feeding

128 Atlantic salmon with a mean initial weight of 52.8 g were kept in indoor tanks with seawater
129 from smoltification and grown to approximately 400 g at Nofima Research Station in
130 Sunndalsøra, Norway. Fish were fed for 26 weeks on one of 10 experimental diets. The
131 experimental diets were isoproteic (46.7 %), isolipidic (25.2 %), and isoenergetic (22.2
132 MJ/kg) and were formulated to cover the nutritional requirements for amino acids and
133 minerals [according to the National Research Council](#) [33]. The experimental diets selected in
134 the present study were formulated to test four dietary levels of EPA, DHA, or a 1:1 mixture of
135 EPA and DHA (0 %, 0.5 %, 1.0 %, and 2.0 % in all dietary groups) ([Table 1](#)). The content of
136 18:3n-3, the precursor of LC-PUFA EPA and DHA, was kept at approximately the same level
137 in all diets (4.7 % of total fatty acids and 1.2 % of the diet). A detailed description of the
138 experimental conditions and dietary composition is given by Bou et al. [34]. At the end of the
139 experiment, three fish per dietary treatment were anesthetized in a MS-222 solution (0.2 g/L)
140 for 5 to 10 min prior to isolation of hepatocytes. The average fish weight was 379.7 ± 96.5 g
141 and no major differences in growth between dietary treatments were observed. The
142 experiment was conducted according to the National Guidelines for Animal Care and Welfare
143 published by the Norwegian Ministry of Education and Research (Forsøksdyrforvaltningens
144 tilsyns- og søknadssystem (FOTS) approval 5354).

145 Hepatocytes isolated from Atlantic salmon fed 10 different experimental diets with different
146 levels of EPA and/or DHA were incubated with radiolabeled ~~α -linolenic acid (18:3n-3)~~ in the
147 presence and absence of LA. The radiolabeled 18:3n-3 was used to measure changes in FA
148 metabolism, desaturation and β -oxidation. In addition, a parallel experiment was done with
149 hepatocytes incubated in the presence or absence of LA to analyze the transcript levels of
150 some lipid related genes. The details of the different methodological and analytical steps are
151 described below.

152 2.3 Isolation of hepatocytes

153 Cells were isolated from three fish per dietary condition and one independent culture per fish
154 was performed. Livers were perfused following a modified two-step collagenase procedure
155 [35, 36] and conducted as previously described [37]. After collagenase perfusion,
156 parenchymal cells were isolated by gently shaking the digested liver in L-15 medium. The
157 suspension of parenchymal cells obtained was filtered through a 100- μ m mesh nylon filter,
158 washed three times in L-15 medium, sedimented by centrifugation for 2 min at 50 \times g, and
159 resuspended in L-15 medium containing 10 % FBS, 0.9 mM sodium bicarbonate, 2 mM L-
160 glutamine, 1 % penicillin-streptomycin solution, and 5 mM HEPES. Cell viability was
161 assessed with 0.4 % Trypan blue. Approximately $4 \cdot 10^5$ hepatocytes/cm² were placed on
162 flasks or six-well plates (25 cm² and 9.6 cm²/well, respectively), coated with laminin, and left
163 to attach for 16 h at 13 °C. Two cell flasks and two wells from each fish were seeded for the
164 experiments. Furthermore, 1 mL of hepatocyte suspension was used to evaluate the effects
165 of the experimental diets on the FA composition of the hepatocytes.

166 2.4 Incubation of hepatocytes with radiolabeled 18:3n-3 and lipoic acid

167 Isolated hepatocytes in flasks were washed with L-15 medium without serum
168 supplementation, and then incubated for 48 h with 21 nmol [1-¹⁴C] 18:3n-3 (7 μ M final
169 concentration) and with or without 0.2 mM LA in a total volume of 3 mL of L-15 medium with
170 2 % FBS. LA dose and incubation time were selected based on previous studies [38].
171 Radiolabeled FA substrate (1.8 μ Ci, 50 mCi/mmol) was added to the medium as a sodium
172 salt bound to FA-free BSA at a molar ratio of FA to BSA of 2.7:1. After incubation, the culture
173 medium was transferred from the culture flasks to vials and centrifuged for 5 min at 50 \times g.
174 The supernatants (culture media) were immediately frozen at -80 °C and stored for
175 determination of radiolabeled lipids and oxidation products. Hepatocytes supplemented with
176 18:3n-3 were washed twice in PBS with 1 % albumin, once with regular PBS, harvested in 2
177 mL PBS, and stored at -80 °C until lipid analysis.

178 Aliquots of 10, 20, 30, 40, and 50 μ L of medium containing radioactive 18:3n-3 were
179 transferred before incubation to vials with 8 mL Ecoscint A scintillation liquid to determine
180 total and specific radioactivity (cpm/nmol FA). Samples were counted in a TRI-CARB 1900
181 TR scintillation counter (Packard Instrument Co., North Chicago, IL, USA).

182 2.5 Lipid extraction and analysis

183 Total lipids were extracted from culture media and cells incubated with radiolabeled 18:3n-3
184 as previously described [39]. The chloroform phase was dried under nitrogen gas and the
185 residual lipid extract was redissolved in 1 mL chloroform. Fifty μ L of chloroform were
186 transferred to vials containing 8 mL scintillation liquid and the remaining volume was used for
187 lipid analysis. Free fatty acids (FFA), phospholipid (PL), monoacylglycerols and,

188 | diacylglycerols (MDG), and triacylglycerol (TAG) were separated by thin-layer
189 chromatography (TLC) using petroleum ether, diethyl ether, and acetic acid (113:20:2 v/v/v)
190 as the mobile phase. Samples were applied on silica gel TLC plates. Lipids were identified by
191 comparison with known standards using a Bioscan AR-2000 Radio-TLC & Imaging Scanner
192 and quantified with the WinScan Application Version 3.12 (Bioscan Inc., Washington, DC,
193 USA). The esterified FA, PL, and NL fractions within the media will be denoted as secreted
194 FA. Spots corresponding to PL and TAG from the cellular lipids were scraped off into glass
195 tubes and trans-methylated for 16 h with 2,2-dimethoxypropane, methanolic HCl, and
196 benzene at room temperature as previously described [40, 41].

197 Total levels of non-labeled lipids were determined by extraction of PL and NL as described
198 above from hepatocytes isolated from three fish in each dietary group. Immediately after
199 isolation, the cells were washed twice in PBS, centrifuged for 2 min at 1000 x g, the
200 supernatant was removed, and the cells were stored at -80 °C until lipid analysis. TLC plates
201 containing these samples were sprayed with 0.2 % (w/v) 2',7'-dichlorofluorescein in methanol
202 and viewed under UV light to identify lipids by comparison with known standards.

203 2.6 FA composition analysis

204 The radioactive FA composition of the PL and NL fractions were determined by reverse-
205 phase HPLC as previously described [42]. The mobile phase contained acetonitrile/H₂O
206 (85:15 v/v, isocratic elution) and was set to a flow rate of 1 mL/min at 30 °C. A reverse-phase
207 Symmetry 3.5 µm C-18 HPLC column from Waters was used. Radioactive FA levels were
208 measured in an A100 radioactive flow detector (Tri-Carb 1900TR; Packard Instruments). FA
209 were identified by comparing sample and FA standards retention times. Nonradioactive FA
210 standards were detected by absorbance at 215 nm in a UV detector (Waters 2996 PDA
211 Detector).

212 Unlabeled methyl esters of FA from the PL and NL fractions of hepatocytes were separated
213 in a GC (Hewlett Packard 6890) with a split injector, an SGE BPX70 capillary column (length
214 60 m, internal diameter 0.25 mm, and film thickness 0.25 µm), a flame ionization detector,
215 and HP Chem Station software. Helium was the carrier gas. The injector and detector
216 temperatures were set to 280 °C. The oven temperature was raised from 50 °C to 180 °C at a
217 rate of 10 °C/min, and then raised to 240 °C at a rate of 0.7 °C/min. The relative amount of
218 each FA was expressed as a percentage of the total amount of FA in the analyzed sample
219 and the absolute amount of FA per gram of tissue was calculated using C23:0 methyl ester
220 as internal standard.

221 2.7 Measurement of ¹⁴CO₂ and acid-soluble products from [1-¹⁴C] 18:3n-3

222 The levels of β -oxidation of 18:3n-3 were measured by counting oxidation products (^{14}C -
223 labeled acid-soluble products (ASP) and $^{14}\text{CO}_2$ formed) essentially as previously described
224 [43]. The amount of gaseous [^{14}C] CO_2 produced during incubation was determined by
225 transferring 1.5 mL of medium to a glass vial which was then sealed. The glass vial
226 contained a central well with a Whatman filter moistened with 0.3 mL of
227 phenylethylamine/methanol (1:1, v/v). The medium was acidified with 0.3 mL 1 M HClO_4 , the
228 samples were incubated for 1 h, and then the wells containing the filters were placed into
229 vials for scintillation counting.

230 The levels of [^{14}C] ASP were determined by acidifying 1 mL of the medium with 0.5 mL ice-
231 cold 2 M HClO_4 and incubating the sample for 60 min at 4 °C. The medium was then
232 centrifuged, and an aliquot of the supernatant was collected for scintillation counting.

233 2.8 Protein content

234 Protein content of cells was determined using the Total Protein kit (Micro Lowry/Peterson's
235 modification) [44, 45] and absorbance at 540 nm in a Titertek Multiscan 96-well plate reader
236 (Labsystem, Finland).

237 2.9 Total RNA extraction, cDNA synthesis, and real-time PCR

238 Isolated hepatocytes in six-well plates were washed with L-15 medium without serum and
239 then incubated for 48 h with or without 0.2 mM LA in 3 mL L-15 medium with 2 % FBS. After
240 incubation, the hepatocytes were washed twice in PBS, harvested in 1 ml Trizol, and stored
241 at -80 °C until RNA extraction.

242 Total RNA was isolated using PureLink Pro 96 RNA Purification Kit according to the
243 manufacturer's instructions. RNA was treated with PureLink DNase to remove any
244 contaminating DNA. RNA concentration was measured using a NanoDrop ND-1000
245 Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). All RNA samples used
246 in our experiments had A260/280 ratios between 2.02 and 2.14. Total RNA (450 ng) was
247 reverse-transcribed into cDNA in a 20- μL reaction using the TaqMan® Reverse Transcription
248 Reagents kit according to the manufacturer's protocol.

249 | PCR primers (Table 42) were designed using the Vector NTI software (Invitrogen, Carlsbad,
250 CA, USA) and synthesized by Invitrogen. The efficiency was checked in ten-fold serial
251 dilutions of cDNA for each primer pair. Real-time PCR was performed in a LightCycler 480
252 (Roche Applied Science, Germany). The PCR master mix consisted of 1 μL forward and
253 reverse primers (final concentrations of 0.5 μM), 4 μL of a 1:10 dilution of cDNA, and 5 μL
254 LightCycler 480 SYBR Green I Master mix. All samples were analyzed in duplicate with a
255 non-template control (NTC) for each gene. The reaction conditions were 95 °C for 5 min, and

256 45 cycles of 95 °C for 15 s and 60 °C for 1 min. The specificity of PCR amplification was
 257 confirmed by melting curve analysis (95 °C for 5 s, 65 °C for 1 min, and then 97 °C). Rpol2,
 258 Ef1 α , and Etif3 were evaluated for use as reference genes, and it was found that the latter
 259 was the most stable. Relative quantification of transcript abundance was calculated using the
 260 $\Delta\Delta\text{CT}$ method and the formula $\Delta\Delta\text{CT} = - [(Ct_{\text{target gene}} - Ct_{\text{Etif3}})_{\text{treatment}} - (Ct_{\text{target gene}} - Ct_{\text{Etif3}})_{\text{control}}]$
 261 [46].

262 2.10 Statistical analysis

263 Flasks or wells were used as experimental units (n=3). Changes in FA composition of the PL
 264 and NL fractions of hepatocytes were analyzed by one-way analysis of variance (ANOVA)
 265 followed by the Tukey's honest significant difference *post hoc* test to detect differences within
 266 dietary groups. All other data were analyzed by a two-way ANOVA using diet and presence
 267 or absence of lipoic acid as effects. Spearman's correlation coefficients were calculated to
 268 estimate the association of cellular EPA or DHA and 18:3n-3 with different FA products.
 269 Differences were considered statistically significant at $P < 0.05$. Values are shown as mean \pm
 270 SEM. All statistical analyses were conducted using the software JMP[®] version 11.2.1 (SAS
 271 Institute Inc., Cary, NC, 1989-2007).

272

273 3. RESULTS

274 3.1 Endogenous FA composition of hepatocytes

275 To test whether FA content of fish was affected by dietary FA, the endogenous FA
 276 composition in salmon hepatocytes was determined. The results show that FA content was
 277 significantly affected by dietary FA. The n-6/n-3 ratio gradually increased in the PL fraction of
 278 hepatocytes of fish fed diets containing less n-3 VLC-PUFA (Table 23), and increasing
 279 dietary levels of EPA and/or DHA significantly increased the content of DHA in the PL
 280 fraction. In contrast, 20:5n-3EPA levels in the PL fraction from fish fed the DHA diets were
 281 similar to those from fish fed the 0 % diet. ~~On the other hand, significantly higher 22:6n-3~~
 282 ~~levels were observed in membranes of fish fed diets with increasing levels of EPA and/or~~
 283 ~~DHA, indicating an active conversion from EPA to DHA.~~ Nevertheless, the highest levels of
 284 22:6n-3DHA were detected in fish fed a diet with 2.0 % DHA. The 22:6n-3DHA content in the
 285 membranes of the deficient group (0 % diet) was reduced three-fold when compared to that
 286 from the 2.0 % DHA dietary group. In contrast, fish fed the 0 % diet ~~more than almost~~
 287 the amount of n-6 FA compared to that of fish fed the 2.0 % diets (2.0% EPA, 2.0% DHA,
 288 and 2.0% EPA+DHA diets). This increase in n-6 FA content was mainly due to increased
 289 levels of 20:4n-6 and 20:3n-6, followed by 18:2n-6. This was reflected on the n-6

290 desaturation index, with the highest value corresponding to hepatocytes isolated from fish
 291 fed the 0 % diet and gradually decreasing as the dietary n-3 VLC-PUFA were increased. The
 292 FA composition of the NL fraction was less affected by dietary lipid (Table 23), although the
 293 amount of PUFA gradually decreased in the NL fraction of hepatocytes as the fish received
 294 diets containing less n-3 VLC-PUFA. This decrease in PUFA was followed by an increase in
 295 MUFA, mainly 18:1 n-9. The amount of PUFA ~~and MUFA~~ was less ~~and more~~ abundant,
 296 ~~respectively~~, in the NL than in the PL fraction, whereas the amount of MUFA was more
 297 abundant in the NL than in the PL fraction. The levels of the 18:3n-3 precursor remained
 298 unaltered regardless of dietary treatment in both fractions. The relative lipid class distribution
 299 between total PL and NL fractions, determined using an internal standard GC approach, was
 300 not altered by dietary treatment, with the majority being in the PL form and representing ~75
 301 %.

302 3.2 Effect of endogenous FA composition and LA supplementation on the metabolism of [1-
 303 ¹⁴C] 18:3n-3

304 To study the dietary and LA effects on the uptake and metabolism of 18:3n-3, Atlantic
 305 salmon hepatocytes isolated from fish fed 10 different diets containing different levels of EPA
 306 and/or DHA were incubated with [1-¹⁴C] 18:3n-3 in the presence or absence of LA for 48 h.
 307 Table 3-4 shows the total uptake and radioactivity distribution from 18:3n-3 recovered in
 308 cellular lipids, water-soluble oxidation (ASP + CO₂) products, and secreted lipids in the
 309 culture media. The majority of 18:3n-3 was taken up by hepatocytes and incorporated into
 310 cellular lipids (12.4 ± 0.17 nmol, corresponding to 59.2 % of added substrate). The level of
 311 incorporation into cellular lipids did not differ between LA-supplemented and control cells. In
 312 contrast, the endogenous FA composition had a significant effect on cellular incorporation of
 313 radiolabeled FA, with the 0 % dietary group presenting the highest incorporation (13.7 ± 0.26
 314 nmol; average value between control and LA-supplemented cells). The level of radiolabeled
 315 secreted lipids did not differ between LA-supplemented and control cells. Nevertheless, the
 316 TAG secretion average in control cells was 1.48 ± 0.51 nmol while that from LA-
 317 supplemented cells was 1.03 ± 0.50 nmol (data not shown). LA addition promoted the
 318 formation of ASP but decreased the production of CO₂ from 18:3n-3. In addition, the amount
 319 of ASP was higher in hepatocytes isolated from fish fed diets containing 1.0 % and 2.0 % n-3
 320 VLC-PUFA (EPA and/or DHA) than in the other dietary groups.

321 Table 4-5 shows the relative distribution of esterified radiolabeled lipids derived from [1-¹⁴C]
 322 18:3n-3. The majority of radiolabeled FA was found in PL, in which an average of 86 % and
 323 76 % of radiolabeled substrate was incorporated in ~~non-supplemented control~~ and LA-
 324 supplemented hepatocytes, respectively. Close to 12 % and 21 % of radiolabeled substrate

325 | was used for TAG production in hepatocytes incubated in LA-free control or LA-supplemented
 326 | medium, respectively on average. Only a minor part of radiolabeled 18:3n-3 was used for
 327 | MDG (2 %) and cholesterol esters (CE) (0.4 %) production in all conditions studied; non-
 328 | esterified free FA were below the detection threshold. In general, a gradual increase in the
 329 | relative production of TAG and a concomitant decrease in PL was found in hepatocytes
 330 | isolated from fish fed with increasing levels of EPA and/or DHA. On the other hand, LA
 331 | consistently decreased the relative production of PL and favored that of all the other neutral
 332 | lipids analyzed.

333 | 3.3 Effect of endogenous FA composition and LA supplementation on the desaturation and
 334 | chain-elongation of [^{14}C] 18:3n-3

335 | The main products of 18:3n-3 in the PL fraction were 20:5n-3EPA and 22:6n-3DHA, followed
 336 | by 20:4n-3 and 20:3n-3 (Table 56). The PL fraction of hepatocytes isolated from fish fed the
 337 | 0 % diet presented the highest content of 18:3n-3 regardless of being cultivated in the
 338 | presence or absence of LA. A gradual decrease in 18:3n-3, 18:4n-3, 20:4n-3, 20:5n-3EPA,
 339 | and 22:5n-3 content was observed in the PL fraction of hepatocytes isolated from fish fed
 340 | with increasing levels of EPA and/or DHA, while that of 20:3n-3 gradually increased. LA
 341 | supplementation in the medium affected 18:3n-3 metabolism (Fig. 1A) in a similar fashion as
 342 | resulting from increasing the dietary content of n-3 ω -LC-PUFA (Fig. 2A). Thus, LA further
 343 | reduced the levels of 18:3n-3, 18:4n-3, 20:4n-3, 20:5n-3EPA, and 22:5n-3 in the PL fraction
 344 | of hepatocytes, whereas it increased 20:3n-3 levels. Surprisingly, endogenous FA
 345 | composition had no significant effect on the production of 22:6n-3DHA. ~~Indeed, the tendency~~
 346 | ~~found was contrary to what would have been expected, with a~~ slightly higher production
 347 | was observed in cells from fish fed with the highest levels of n-3 ω -LC-PUFA. However, a
 348 | significant interaction between LA and diet was observed in which LA only promoted the
 349 | presence of 22:6n-3DHA in the PL fraction of hepatocytes from fish fed 0 % and 0.5 % EPA
 350 | and/or DHA. Interestingly, the DHA contents in the PL fraction of hepatocytes from fish fed
 351 | 0.5 % EPA, 0.5 % DHA, and 0.5 % EPA+DHA diets were fairly similar ($19.7 \pm 0.52 \text{ mol\%}$;
 352 | average value of the aforementioned diets), indicating that endogenous DHA content may be
 353 | the factor modulating the effects of LA.

354 | The main product from 18:3n-3 found in the NL fraction was 20:3n-3, ~~followed by 22:6n-3 but~~
 355 | ~~smaller amounts of DHA~~, 20:5n-3EPA, and 18:4n-3 were also produced (Table 67).
 356 | However, the production of 18:4n-3 and 20:5n-3EPA was not affected by endogenous FA
 357 | composition or by LA addition. A gradual increase in the deposition of 18:3n-3, 20:3n-3, and
 358 | 22:6n-3DHA contents ~~was observed~~ in the NL fraction of hepatocytes isolated from fish fed
 359 | with increasing dietary levels of EPA and/or DHA or supplemented with LA was observed. ~~LA~~

360 ~~addition to the medium consistently promoted the production of these three FA in all dietary~~
361 ~~groups, further stimulating the effect of dietary n-3 VLC-PUFA.~~ On the other hand, 20:4n-3
362 and 22:5n-3 levels were below the detection threshold in several experimental groups. LA
363 supplementation and dietary n-3 LC-PUFA had similar effects on the picomoles recovered in
364 18:3n-3 and its products in the NL fraction (Fig. 1B and 2B).~~Fig. 1B and 2B show the main~~
365 ~~effects on the NL fraction of LA and dietary n-3 VLC-PUFA, respectively, and Fig. 3 shows~~
366 The total DHA production represented as the sum of recovered picomoles in PL and NL
367 showed that LA supplementation increased DHA production in hepatocytes isolated from fish
368 fed ≤ 0.5% EPA and/or DHA (Fig. 3).

369 To determine the association strength between cellular EPA or DHA and the desaturation
370 and elongation of 18:3n-3 substrate to its different FA products, Spearman's correlation
371 coefficients were calculated (Table 78). DHA cellular content had a stronger association with
372 all FA produced compared to that from EPA cellular content.~~, indicating that endogenous~~
373 ~~DHA influences the pathway activity to a higher degree than endogenous EPA.~~

374 3.4 Effect of endogenous FA composition and LA supplementation on the transcriptional
375 regulation of the n-3 biosynthetic pathway

376 Because differences in 18:3n-3 desaturation and elongation were observed in hepatocytes
377 isolated from fish fed with different levels of EPA and/or DHA cultivated in LA-free or LA-
378 supplemented medium, we further investigated whether these differences were associated
379 with changes in transcript abundance of genes encoding proteins related to lipid metabolism.
380 Transcript levels of genes coding for *srebp1*, *aco*, *elovl2*, *elovl5b*, *Δ5fad*, and *Δ6fad_a* are
381 shown in Fig. 4. Transcript levels of all evaluated genes changed as a result of diet
382 composition and, consequently, of endogenous FA composition. mRNA levels of *srebp1* and
383 *aco* decreased in all dietary groups compared to those of the 0 % diet group, whereas *Δ5fad*
384 mRNA levels increased. *Δ6fad_a*, *elovl2*, and *elovl5b* gene transcripts were modulated in a
385 dose-dependent manner, with decreasing levels as n-3 VLC-PUFA levels increased. LA
386 addition only increased gene transcript levels of the two elongases assessed.

387

388 4. DISCUSSION

389 One of the main aims of the study was to investigate the effects of different dietary levels of
390 EPA and/or DHA on the fish 18:3n-3 metabolism. The endogenous FA composition of
391 hepatocytes was influenced by dietary FA composition. These results are in agreement with
392 several studies in salmonids where different lipid sources were tested [5, 25, 37, 47, 48]. In
393 general, increasing levels of dietary EPA increased cellular levels of EPA, 22:5n-3DPA, and

394 DHA, whereas increasing DHA dietary levels only increased cellular DHA content. In
395 addition, decreasing dietary n-3 levels increased the levels of ~~the pro-inflammatory FA~~ 20:3n-
396 6 and 20:4n-6 in the PL fraction of hepatocytes, showing a stimulation of the n-6 pathway by
397 18:2n-6 when EPA and DHA are lacking. It has been extensively reported that feeding fish
398 with a VO-based diet leads to increased activity of the n-6 and n-3 biosynthetic pathways [2,
399 24, 25, 49, 50]. Two main explanations have been proposed for the stimulation of the
400 pathway: an increase in C₁₈ substrate availability, and a lack of C₂₀ and C₂₂ PUFA ~~that would~~
401 ~~otherwise lead to a decrease caused by product inhibition~~. However, determining which of
402 these two factors might have a bigger effect is not trivial, because so far the practical diets
403 tested with high levels of n-3 ~~LC-HPUFA~~ had low levels of C₁₈ PUFA and vice versa. In the
404 present study, the dietary levels of 18:3n-3 were kept constant at 1.2 ± 0.02 % in all tested
405 diets. In addition, the levels of 18:2n-6 were kept stable at 5.4 ± 0.08 %, providing a steady
406 18:2n-6/18:3n-3 ratio of 4.5. These conditions allowed us to rule out a possible effect caused
407 by competition between both substrates for the enzymes and to relate changes in the
408 endogenous n-3 biosynthetic pathway activity directly to dietary and cellular n-3 ~~VLC~~-PUFA
409 content.

410 Hepatocytes isolated from fish fed with increasing levels of n-3 ~~VLC~~-PUFA showed a
411 significant decrease in the production of radiolabeled 20:4n-3, EPA, and ~~22:5n-3DPA~~ in the
412 PL fraction, and the production of these FA was further reduced in cells supplemented with
413 LA. These results are in agreement with previous studies showing a reduction in the FA
414 biosynthetic pathway linked to ~~VLC~~-PUFA availability [25, 26]. Strikingly, neither diet nor LA
415 supplement had any effect on the levels of radiolabeled esterified DHA in the PL fraction.
416 However, these two factors interacted, and thus LA exposure led to increased elongation and
417 desaturation of 18:3n-3 to DHA in hepatocytes from fish fed diets containing 0 % and 0.5 %
418 EPA and/or DHA. In contrast, LA exposure of cells from fish fed with higher dietary levels of
419 EPA and/or DHA resulted in a reduced cellular capacity to transform 18:3n-3 into DHA. It is
420 noteworthy that the endogenous DHA contents in the PL fractions of fish fed 0.5% EPA, 0.5
421 % DHA, and 0.5 % EPA+DHA were fairly similar (19.7 ± 0.52 mol%), suggesting that cellular
422 DHA may be modulating the effects of LA. In a recent study, dietary LA supplementation also
423 increased the DHA content in the liver of diet-induced ~~non~~ nonalcoholic fatty liver disease
424 mice [51]. Despite the observed stimulation of DHA synthesis by LA, it had no effect on the
425 transcriptional regulation of desaturase genes. Incubation of salmon hepatocytes with
426 sesamine, another bioactive component, was reported to also increase the conversion of
427 18:3n-3 to DHA but, paradoxically, decrease $\Delta 5fad$ and $\Delta 6fad$ gene transcripts [52]. On the
428 other hand, the NL fraction of hepatocytes isolated from fish fed with increasing levels of n-3
429 ~~VLC~~-PUFA showed a significant increase in DHA production that was further increased by

430 LA addition. However, this LA-induced increase did not compensate for the aforementioned
431 decrease in DHA production in the PL fraction of hepatocytes isolated from fish fed diets
432 containing EPA and/or DHA at dietary levels of 1.0 % or above.

433 In the n-3 FA pathway, 18:3n-3 can either be desaturated via $\Delta 6$ desaturase to 18:4n-3 or
434 elongated via *Elovl5* to 20:3n-3. Desaturation was favored by low dietary levels of n-3 ω -
435 PUFA in the PL fraction of hepatocytes, whereas the addition of LA had no effect in the
436 production of 18:4n-3. In contrast, elongation of 18:3n-3 to 20:3n-3 was promoted in both
437 lipid fractions by increasing dietary levels of n-3 ω -PUFA and by LA addition. This is in
438 agreement with previous studies showing that hepatocytes isolated from Atlantic salmon fed
439 FO-based diet rich in n-3 ω -PUFA [48], supplemented with DHA in the culture medium [5],
440 or supplemented with LA [38], significantly enhanced the production of 20:3n-3. Furthermore,
441 the cellular DHA content in control cells was strongly correlated (0.883; $P < 0.0001$) to the
442 amount of 20:3n-3. This FA was considered to be a dead-end product of the pathway.
443 However, it was recently shown that not only mammalian [13], but also teleostei, $\Delta 6$ Fads
444 possess $\Delta 8$ desaturase activity [12], and thus 20:3n-3 can be desaturated to 20:4n-3, which
445 can then be reincorporated into the pathway for further $\Delta 5$ desaturation. Even though the
446 activity of the $\Delta 8$ pathway in freshwater/diadromous species has been reported to be low
447 compared to that from other marine teleosts [12], it might provide an alternative route for the
448 synthesis of 20:5n-3EPA from 18:3n-3 that does not involve a $\Delta 6$ desaturation. As suggested
449 by the correlation coefficients in our study, cellular DHA content seems to have a major effect
450 modulating the activity of the pathway by regulating the conversion of 18:3n-3 to either
451 20:3n-3 or 18:4n-3. The decrease in content of the desaturation product 18:4n-3 with
452 increasing dietary n-3 ω -PUFA is also consistent with the decrease in *$\Delta 6fad_a$* transcript
453 abundance. However, the n-3 ω -PUFA dietary stimulation of 20:3n-3 production was not
454 accompanied by an up-regulation of *e/ovl5b* transcripts in the present study. LA
455 supplementation, on the contrary, increased both *e/ovl5b* transcript abundance and 20:3n-3
456 production. A recent study suggested that land-locked salmon, which remain in freshwater
457 their whole life and thus are naturally surrounded by lower levels of n-3 PUFA, might have a
458 higher $\Delta 8$ activity compared to their farmed counterparts [53]. In the present study,
459 radioactivity recovered in 20:4n-3 was significantly reduced in the PL fraction of cells by
460 increasing levels of n-3 ω -PUFA, and the addition of LA reduced it further. Since
461 radioactivity in 20:4n-3 could be the result of either $\Delta 6$ or $\Delta 8$ activity, it is difficult to draw
462 conclusions. Knowledge of $\Delta 8$ activity regulation is still limited, and thus the $\Delta 8$ desaturase
463 activity of salmon *$\Delta 6fad_a$* or how diet interacts with this alternative pathway remain to be
464 explored, emphasizing the need for further research. In control cells, despite the decrease in
465 20:4n-3, 20:5n-3EPA, and *$\Delta 6fad_a$* mRNA levels with increasing dietary n-3 ω -PUFA, an

466 increase in radiolabeled DHA was observed. Therefore, it is possible that inhibition of $\Delta 6$
467 activity is compensated by $\Delta 8$ or $\Delta 4$ activity to provide DHA. A functional $\Delta 4fads$ was first
468 identified in several teleost species [15-18], and recently it has also been characterized in
469 human cancer cells [20]. However, if this desaturation step is of importance in non-cancer
470 human cells is currently unknown. In addition, whether Atlantic salmon possess this ability,
471 and if so, what is the capacity of this direct pathway remain to be explored. Dietary PUFA
472 play a role as ligands of key transcription factors, including SREBP1 [23]. The transcript
473 levels of this transcription factor gene were decreased by dietary n-3 ω -3 LC-PUFA. These
474 results are in agreement with the regulation described in mammals, in which SREBP1 is
475 activated by low levels of cholesterol and is inhibited by high levels of PUFA [54].

476 After entering the cell, radiolabeled FA substrate can be used for energy purposes by going
477 through β -oxidation and extensive carbon recycling, or can be esterified into cellular lipids. In
478 the present study, radiolabeled 18:3n-3 or its FA products were preferentially incorporated
479 into PL with increasing percentages found in hepatocytes isolated from fish fed with
480 decreasing levels of n-3 ω -3 LC-PUFA, and that consequently contained significantly lower
481 amounts of these FA. In contrast, little radioactivity was recovered in TAG, with increasing
482 percentages observed in hepatocytes isolated from fish fed with increasing levels of n-3
483 ω -3 LC-PUFA. These results are in agreement with several previous studies in salmonid
484 hepatocytes and muscle cells showing that PUFA are predominately incorporated into PL
485 [47, 55, 56]. In contrast, another study showed that radioactivity was mostly recovered in
486 salmon hepatocytes in the form of TAG [48]. However, in this last study, hepatocytes in
487 suspension were incubated with radiolabeled FA for only 2 h, which may explain the
488 discrepancy in the results.

489 In this study, we also demonstrated clear effects of LA supplementation on FA metabolism in
490 Atlantic salmon hepatocytes. Even though the amount of radiolabeled cellular lipids was not
491 influenced by LA supplementation, LA significantly reduced the esterification of 18:3n-3 and
492 its products into PL and increased the content of these compounds in storage depots. In
493 addition, this increased incorporation into cellular TAG was paralleled by a decrease in TAG
494 secretion to the media. In mammals, even though the exact mechanisms are still unclear,
495 strong evidence supports the effects of LA on TAG metabolism [57]. Reduced levels of
496 esterified radiolabelled TAG in the media indicate that LA reduce the secretion of TAG-rich
497 VLDL from hepatocytes to blood, in agreement with ~~Despite of some conflicting results, the~~
498 majority of the studies ~~in mammals show that LA reduce blood TAG [57-59], which is in~~
499 agreement with the effect of LA in salmon hepatocytes observed in the present study.

500 | Formation of ASP oxidation products was generally enhanced in hepatocytes with the
501 | highest endogenous level of DHA, whereas no dietary modulation of CO₂ production was
502 | observed. LA supplementation, on the other hand, significantly increased ASP and
503 | decreased CO₂ production. LA has been shown to decrease lipid accumulation in non-
504 | adipose tissues by stimulating hepatic β-oxidation in mice [60] and in rat skeletal muscle [61].
505 | On the other hand, LA inhibited the oxidation of FFA in primary rat hepatocytes and
506 | increased pyruvate oxidation [62]. Because in our experiments LA significantly increased the
507 | production of ASP, we speculate that LA may increase DHA production by stimulating
508 | peroxisomal β-oxidation [56]. However, the gene transcript abundance of acyl-CoA oxidase
509 | (*aco*), the rate-limiting enzyme of peroxisomal β-oxidation, decreased by n-3 VLC-PUFA,
510 | whereas addition of LA did not have any effect on its regulation. Lack of regulation of this
511 | enzyme by FA at both protein and transcript levels has been reported in rainbow trout
512 | hepatocytes [47] and Atlantic salmon hepatocytes [52], despite showing an increased
513 | production of β-oxidation products.

514 | This study strongly indicates that LA plays a role influencing n-3 FA metabolism in Atlantic
515 | salmon hepatocytes by enhancing the production of DHA, but this production is restricted by
516 | high cellular DHA content. In addition, increasing dietary levels of EPA and/or DHA reduced
517 | salmon's innate production of 18:4n-3, 20:4n-3, EPA, and DPA22:5n-3, but DHA production
518 | was maintained, even showing a slight increase with high dietary EPA and/or DHA. To
519 | determine the exact mechanisms by which LA and dietary n-3 VLC-PUFA increase the levels
520 | of health-beneficial VLC-PUFA, further research on the Δ6, Δ8, and Δ4 activities is required.

521

522 | **ACKNOWLEDGMENTS**

523 | The authors would like to thank Målfrid Tofteberg Bjerke and Inger Øien Kristiansen for their
524 | skilful technical assistance. This work was carried out with support from the Norwegian
525 | Research Council (grant number NFR 224913). There are no conflicts of interest to report.

526 REFERENCES

- 527 1. Ytrestøl T, Aas TS, and Åsgård T (2015) Utilisation of feed resources in production of Atlantic
528 salmon (*Salmo salar*) in Norway. *Aquaculture* 448: 365-374
- 529 2. Tocher DR (2015) Omega-3 long-chain polyunsaturated fatty acids and aquaculture in
530 perspective. *Aquaculture* 449: 94-107
- 531 3. Tocher DR, Leaver MJ, and Hodgson PA (1998) Recent advances in the biochemistry and
532 molecular biology of fatty acyl desaturases. *Progress in lipid research* 37: 73-117
- 533 4. Castro LF, Tocher DR, and Monroig O (2016) Long-chain polyunsaturated fatty acid
534 biosynthesis in chordates: Insights into the evolution of Fads and Elovl gene repertoire.
535 *Progress in lipid research* 62: 25-40
- 536 5. Ruyter B, Røsjø C, Einen O, and Thomassen MS (2000) Essential fatty acids in Atlantic salmon:
537 time course of changes in fatty acid composition of liver, blood and carcass induced by a diet
538 deficient in n-3 and n-6 fatty acids. *Aquaculture Nutrition* 6: 109-117
- 539 6. Ruyter B, and Thomassen MS (1999) Metabolism of n-3 and n-6 fatty acids in Atlantic salmon
540 liver: stimulation by essential fatty acid deficiency. *Lipids* 34: 1167-1176
- 541 7. Zheng X, Tocher DR, Dickson CA, Bell JG, and Teale AJ (2005) Highly unsaturated fatty acid
542 synthesis in vertebrates: new insights with the cloning and characterization of a delta6
543 desaturase of Atlantic salmon. *Lipids* 40: 13-24
- 544 8. Hastings N, Agaba MK, Tocher DR, Zheng X, Dickson CA, Dick JR, and Teale AJ (2004)
545 Molecular cloning and functional characterization of fatty acyl desaturase and elongase
546 cDNAs involved in the production of eicosapentaenoic and docosahexaenoic acids from
547 alpha-linolenic acid in Atlantic salmon (*Salmo salar*). *Marine biotechnology* (New York, NY) 6:
548 463-474
- 549 9. Monroig O, Zheng X, Morais S, Leaver MJ, Taggart JB, and Tocher DR (2010) Multiple genes
550 for functional 6 fatty acyl desaturases (Fad) in Atlantic salmon (*Salmo salar* L.): gene and
551 cDNA characterization, functional expression, tissue distribution and nutritional regulation.
552 *Biochimica et biophysica acta* 1801: 1072-1081
- 553 10. Carmona-Antonanzas G, Monroig O, Dick JR, Davie A, and Tocher DR (2011) Biosynthesis of
554 very long-chain fatty acids (C>24) in Atlantic salmon: cloning, functional characterisation, and
555 tissue distribution of an Elovl4 elongase. *Comparative biochemistry and physiology Part B,
556 Biochemistry & molecular biology* 159: 122-129
- 557 11. Morais S, Monroig O, Zheng X, Leaver MJ, and Tocher DR (2009) Highly unsaturated fatty acid
558 synthesis in Atlantic salmon: characterization of ELOVL5- and ELOVL2-like elongases. *Marine
559 biotechnology* (New York, NY) 11: 627-639
- 560 12. Monroig Ó, Li Y, and Tocher DR (2011) Delta-8 desaturation activity varies among fatty acyl
561 desaturases of teleost fish: High activity in delta-6 desaturases of marine species.
562 *Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology* 159:
563 206-213
- 564 13. Park WJ, Kothapalli KS, Lawrence P, Tyburczy C, and Brenna JT (2009) An alternate pathway
565 to long-chain polyunsaturates: the FADS2 gene product Delta8-desaturates 20:2n-6 and
566 20:3n-3. *Journal of lipid research* 50: 1195-1202
- 567 14. Sprecher H (2000) Metabolism of highly unsaturated n-3 and n-6 fatty acids. *Biochimica et
568 Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids* 1486: 219-231
- 569 15. Li Y, Monroig O, Zhang L, Wang S, Zheng X, Dick JR, You C, and Tocher DR (2010) Vertebrate
570 fatty acyl desaturase with Δ4 activity. *Proceedings of the National Academy of Sciences* 107:
571 16840-16845
- 572 16. Morais S, Castanheira F, Martinez-Rubio L, Conceicao LE, and Tocher DR (2012) Long chain
573 polyunsaturated fatty acid synthesis in a marine vertebrate: ontogenetic and nutritional
574 regulation of a fatty acyl desaturase with Delta4 activity. *Biochimica et biophysica acta* 1821:
575 660-671

- 576 17. Kuah MK, Jaya-Ram A, and Shu-Chien AC (2015) The capacity for long-chain polyunsaturated
577 fatty acid synthesis in a carnivorous vertebrate: Functional characterisation and nutritional
578 regulation of a Fads2 fatty acyl desaturase with Delta4 activity and an Elovl5 elongase in
579 striped snakehead (*Channa striata*). *Biochimica et biophysica acta* 1851: 248-260
- 580 18. Fonseca-Madrigal J, Navarro JC, Hontoria F, Tocher DR, Martínez-Palacios CA, and Monroig Ó
581 (2014) Diversification of substrate specificities in teleostei Fads2: characterization of Δ4 and
582 Δ6Δ5 desaturases of *Chirostoma estor*. *Journal of lipid research* 55: 1408-1419
- 583 19. Morais S, Mourente G, Martinez A, Gras N, and Tocher DR (2015) Docosahexaenoic acid
584 biosynthesis via fatty acyl elongase and Delta4-desaturase and its modulation by dietary lipid
585 level and fatty acid composition in a marine vertebrate. *Biochimica et biophysica acta* 1851:
586 588-597
- 587 20. Park HG, Park WJ, Kothapalli KS, and Brenna JT (2015) The fatty acid desaturase 2 (FADS2)
588 gene product catalyzes Delta4 desaturation to yield n-3 docosahexaenoic acid and n-6
589 docosapentaenoic acid in human cells. *FASEB journal : official publication of the Federation
590 of American Societies for Experimental Biology* 29: 3911-3919
- 591 21. Tocher DR, Bell JG, Dick JR, and Sargent JR (1997) Fatty acyl desaturation in isolated
592 hepatocytes from Atlantic salmon (*Salmo salar*): stimulation by dietary borage oil containing
593 gamma-linolenic acid. *Lipids* 32: 1237-1247
- 594 22. Tocher DR, Bell JG, MacGlaughlin P, McGhee F, and Dick JR (2001) Hepatocyte fatty acid
595 desaturation and polyunsaturated fatty acid composition of liver in salmonids: effects of
596 dietary vegetable oil. *Comparative biochemistry and physiology Part B, Biochemistry &
597 molecular biology* 130: 257-270
- 598 23. Carmona-Antonanzas G, Tocher DR, Martinez-Rubio L, and Leaver MJ (2014) Conservation of
599 lipid metabolic gene transcriptional regulatory networks in fish and mammals. *Gene* 534: 1-9
- 600 24. Zheng X, Torstensen BE, Tocher DR, Dick JR, Henderson RJ, and Bell JG (2005) Environmental
601 and dietary influences on highly unsaturated fatty acid biosynthesis and expression of fatty
602 acyl desaturase and elongase genes in liver of Atlantic salmon (*Salmo salar*). *Biochimica et
603 biophysica acta* 1734: 13-24
- 604 25. Tocher DR, Bell JG, Dick JR, and Crampton VO (2003) Effects of dietary vegetable oil on
605 Atlantic salmon hepatocyte fatty acid desaturation and liver fatty acid compositions. *Lipids*
606 38: 723-732
- 607 26. Thomassen MS, Rein D, Berge GM, Østbye T-K, and Ruyter B (2012) High dietary EPA does
608 not inhibit Δ5 and Δ6 desaturases in Atlantic salmon (*Salmo salar* L.) fed rapeseed oil diets.
609 *Aquaculture*
- 610 27. Leaver MJ, Bautista JM, Björnsson BT, Jönsson E, Krey G, Tocher DR, and Torstensen BE
611 (2008) Towards Fish Lipid Nutrigenomics: Current State and Prospects for Fin-Fish
612 Aquaculture. *Reviews in Fisheries Science* 16: 73-94
- 613 28. Betancor MB, Sprague M, Sayanova O, Usher S, Campbell PJ, Napier JA, Caballero MJ, and
614 Tocher DR (2015) Evaluation of a high-EPA oil from transgenic *Camelina sativa* in feeds for
615 Atlantic salmon (*Salmo salar* L.): Effects on tissue fatty acid composition, histology and gene
616 expression. *Aquaculture* 444: 1-12
- 617 29. Brenna JT, Salem Jr N, Sinclair AJ, and Cunnane SC (2009) α-Linolenic acid supplementation
618 and conversion to n-3 long-chain polyunsaturated fatty acids in humans. *Prostaglandins,
619 Leukotrienes and Essential Fatty Acids* 80: 85-91
- 620 30. Prieto-Hontoria PL, Perez-Matute P, Fernandez-Galilea M, Bustos M, Martinez JA, and
621 Moreno-Aliaga MJ (2011) Role of obesity-associated dysfunctional adipose tissue in cancer: a
622 molecular nutrition approach. *Biochimica et biophysica acta* 1807: 664-678
- 623 31. Bast A, and Haenen GR (2003) Lipoic acid: a multifunctional antioxidant. *BioFactors (Oxford,
624 England)* 17: 207-213
- 625 32. Trattner S, Pickova J, Park KH, Rinchar J, and Dabrowski K (2007) Effects of α-lipoic and
626 ascorbic acid on the muscle and brain fatty acids and antioxidant profile of the South
627 American pacu *Piaractus mesopotamicus*. *Aquaculture* 273: 158-164

- 628 33. Council NR (2011) Nutrient requirements of fish and shrimp. National academies press
629 Washington, DC, USA
- 630 34. Bou M, Berge GM, Baeverfjord G, Sigholt T, Østbye TK, Romarheim OH, Hatlen B, Leeuwis R,
631 Venegas C, and Ruyter B (Manuscript accepted) Requirements of omega-3 very long-chain
632 polyunsaturated fatty acids in Atlantic salmon (*Salmo salar* L): effects of different dietary
633 levels of EPA and DHA on fish performance and tissue composition and integrity The British
634 journal of nutrition
- 635 35. Dannevig BH, and Berg T (1985) Endocytosis of galactose-terminated glycoproteins by
636 isolated liver cells of the rainbow trout (*Salmo gairdneri*). Comparative biochemistry and
637 physiology B, Comparative biochemistry 82: 683-688
- 638 36. Seglen PO (1976) Preparation of isolated rat liver cells. Methods in cell biology 13: 29-83
- 639 37. Kjær MA, Vegusdal A, GjØgen T, Rustan AC, Todorčević M, and Ruyter B (2008) Effect of
640 rapeseed oil and dietary n-3 fatty acids on triacylglycerol synthesis and secretion in Atlantic
641 salmon hepatocytes. Biochimica et biophysica acta 1781: 112-122
- 642 38. Schiller Vestergren AL, Trattner S, Mraz J, Ruyter B, and Pickova J (2011) Fatty acids and gene
643 expression responses to bioactive compounds in Atlantic salmon (*Salmo salar* L.)
644 hepatocytes. Neuro endocrinology letters 32 Suppl 2: 41-50
- 645 39. Folch J, Lees M, and Sloane Stanley GH (1957) A simple method for the isolation and
646 purification of total lipides from animal tissues. The Journal of biological chemistry 226: 497-
647 509
- 648 40. Mason ME, and Waller GR (1964) Dimethoxypropane Induced Transesterification of Fats and
649 Oils in Preparation of Methyl Esters for Gas Chromatographic Analysis. Analytical Chemistry
650 36: 583-586
- 651 41. Hoshi M, Williams M, and Kishimoto Y (1973) Esterification of fatty acids at room
652 temperature by chloroform-methanolic HCl-cupric acetate. Journal of lipid research 14: 599-
653 601
- 654 42. Narce M, Gresti J, and Bezdard J (1988) Method for evaluating the bioconversion of
655 radioactive polyunsaturated fatty acids by use of reversed-phase liquid chromatography.
656 Journal of chromatography 448: 249-264
- 657 43. Christiansen R, Borrebaek B, and Bremer J (1976) The effect of (-)-carnitine on the
658 metabolism of palmitate in liver cells isolated from fasted and refeed rats. FEBS Letters 62:
659 313-317
- 660 44. Peterson GL (1977) A simplification of the protein assay method of Lowry et al. which is more
661 generally applicable. Analytical Biochemistry 83: 346-356
- 662 45. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the
663 Folin phenol reagent. The Journal of biological chemistry 193: 265-275
- 664 46. Livak KJ, and Schmittgen TD (2001) Analysis of Relative Gene Expression Data Using Real-
665 Time Quantitative PCR and the 2- $\Delta\Delta$ CT Method. Methods 25: 402-408
- 666 47. Randall KM, Drew MD, Øverland M, Østbye TK, Bjerke M, Vogt G, and Ruyter B (2013) Effects
667 of dietary supplementation of coriander oil, in canola oil diets, on the metabolism of [1- 14 C]
668 18:3n-3 and [1- 14 C] 18:2n-6 in rainbow trout hepatocytes. Comparative Biochemistry and
669 Physiology Part B: Biochemistry and Molecular Biology 166: 65-72
- 670 48. Stubhaug I, Tocher DR, Bell JG, Dick JR, and Torstensen BE (2005) Fatty acid metabolism in
671 Atlantic salmon (*Salmo salar* L.) hepatocytes and influence of dietary vegetable oil.
672 Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1734: 277-288
- 673 49. Fonseca-Madrigal J, Bell JG, and Tocher DR (2006) Nutritional and environmental regulation
674 of the synthesis of highly unsaturated fatty acids and of fatty-acid oxidation in Atlantic
675 salmon (*Salmo salar* L.) enterocytes and hepatocytes. Fish Physiology and Biochemistry 32:
676 317-328
- 677 50. Ruyter B, Røsjø C, Grisdale-Helland B, Rosenlund G, Obach A, and Thomassen MS (2003)
678 Influence of temperature and high dietary linoleic acid content on esterification, elongation,
679 and desaturation of PUFA in Atlantic salmon hepatocytes. Lipids 38: 833-840

- 680 51. Stanković MN, Mladenović D, Ninković M, Đuričić I, Šobajić S, Jorgačević B, de Luka S,
681 Vukicevic RJ, and Radosavljević TS (2014) The Effects of α -Lipoic Acid on Liver Oxidative
682 Stress and Free Fatty Acid Composition in Methionine–Choline Deficient Diet-Induced NAFLD.
683 Journal of Medicinal Food 17: 254-261
- 684 52. Trattner S, Ruyter B, Østbye TK, Gjøen T, Zlabek V, Kamal-Eldin A, and Pickova J (2008)
685 Sesamin increases alpha-linolenic acid conversion to docosahexaenoic acid in atlantic salmon
686 (*Salmo salar* L.) hepatocytes: role of altered gene expression. Lipids 43: 999-1008
- 687 53. Betancor MB, Olsen RE, Solstorn D, Skulstad OF, and Tocher DR (2016) Assessment of a land-
688 locked Atlantic salmon (*Salmo salar* L.) population as a potential genetic resource with a
689 focus on long-chain polyunsaturated fatty acid biosynthesis. Biochimica et Biophysica Acta
690 (BBA) - Molecular and Cell Biology of Lipids 1861: 227-238
- 691 54. Espenshade PJ (2006) SREBPs: sterol-regulated transcription factors. Journal of Cell Science
692 119: 973-976
- 693 55. Moya-Falcón C, Thomassen MS, Jakobsen JV, and Ruyter B (2005) Effects of dietary
694 supplementation of rapeseed oil on metabolism of [$1-^{14}$ C] 18:1n-9, [$1-^{14}$ C] 20:3n-6, and [$1-^{14}$ C]
695 20:4n-3 in atlantic salmon hepatocytes. Lipids 40: 709-717
- 696 56. Vegusdal A, Ostbye TK, Tran TN, Gjoen T, and Ruyter B (2004) Beta-oxidation, esterification,
697 and secretion of radiolabeled fatty acids in cultivated Atlantic salmon skeletal muscle cells.
698 Lipids 39: 649-658
- 699 57. Pashaj A, Xia M, and Moreau R (2015) α -Lipoic acid as a triglyceride-lowering
700 nutraceutical. Canadian journal of physiology and pharmacology 93: 1029-1041
- 701 58. Butler JA, Hagen TM, and Moreau R (2009) Lipoic acid improves hypertriglyceridemia by
702 stimulating triacylglycerol clearance and downregulating liver triacylglycerol secretion.
703 Archives of biochemistry and biophysics 485: 63-71
- 704 59. Seo EY, Ha AW, and Kim WK (2012) α -Lipoic acid reduced weight gain and improved the lipid
705 profile in rats fed with high fat diet. Nutrition Research and Practice 6: 195-200
- 706 60. Yang R-I, Li W, Shi Y-H, and Le G-W (2008) Lipoic acid prevents high-fat diet-induced
707 dyslipidemia and oxidative stress: A microarray analysis. Nutrition 24: 582-588
- 708 61. Lee WJ, Song KH, Koh EH, Won JC, Kim HS, Park HS, Kim MS, Kim SW, Lee KU, and Park JY
709 (2005) Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle.
710 Biochemical and biophysical research communications 332: 885-891
- 711 62. Walgren JL, Amani Z, McMillan JM, Locher M, and Buse MG (2004) Effect of R(+)- α -Lipoic acid
712 on pyruvate metabolism and fatty acid oxidation in rat hepatocytes. Metabolism 53: 165-173

713

714

715 **FIGURE LEGENDS**

716 **Fig.1** Main changes produced by lipoic acid supplementation in esterification of [1-¹⁴C] 18:3n-
717 3 and its products into phospholipids (A) and neutral lipids (B). Data are shown as mean ±
718 SEM (n=3).

719 **Fig. 2** Main changes produced by increasing dietary levels of EPA and/or DHA in
720 esterification of [1-¹⁴C] 18:3n-3 and its products into phospholipids (A) and neutral lipids (B).
721 Data are shown as mean ± SEM (n=6).

722 **Fig. 3** Total radiolabeled docosahexaenoic acid (DHA; 22:6n-3) esterified into cellular lipids
723 (PL+NL) in hepatocytes incubated with [1-¹⁴C] 18:3n-3 in the presence or absence of lipoic
724 acid. Cells were isolated from fish fed diets containing different levels of EPA and/or DHA for
725 26 weeks before the experiment. Data are shown as mean ± SEM (n=3).

726 **Fig. 4** Relative changes in mRNA transcript abundance of genes involved in the n-3 fatty
727 acid biosynthetic pathway. Atlantic salmon hepatocytes cultivated in the presence or
728 absence of lipoic acid were isolated from fish fed 10 experimental diets containing different
729 levels of EPA and/or DHA for 26 weeks. Samples (n=3) were analyzed using real-time qPCR
730 and data are presented as $-\Delta\Delta Ct \pm SEM$. Cells isolated from fish fed the 0 % diet were used
731 as control and values were set to zero. Results are compared by two-way analysis of
732 variance (diet and lipoic acid as factors; $P < 0.05$).

733 TABLES

734 Table 1. Fatty acid composition (mol%) in the experimental diets.

	0%	0.5% EPA	1.0% EPA	2.0% EPA	0.5% DHA	1.0% DHA	2.0% DHA	0.5% EPA+DHA	1.0% EPA+DHA	2.0% EPA+DHA
16:0	17.7	17.2	16.8	15.9	17.3	16.9	16.0	17.2	16.8	16.0
18:0	4.2	4.1	4.0	3.9	4.2	4.2	4.2	4.2	4.1	4.1
SFA ¹	23.0	22.4	21.9	20.7	22.3	22.3	21.3	22.5	22.1	21.1
18:1n-9	44.5	43.4	41.7	38.3	43.5	42.0	39.4	43.1	41.8	39.0
MUFA ²	47.3	45.8	44.2	41.0	46.3	44.9	42.4	45.8	44.7	41.6
18:2n-6	23.7	23.0	22.5	21.3	23.2	22.8	21.5	23.1	22.5	21.5
18:3n-3	5.3	5.1	4.9	4.9	5.1	4.9	4.6	5.1	5.0	4.6
C18 PUFA ³	29.0	28.3	27.7	26.5	28.5	27.8	26.3	28.4	27.6	26.3
20:5n-3	0.0	2.2	4.3	8.4	0.4	0.7	1.4	1.4	2.5	5.1
22:6n-3	0.1	0.6	1.1	1.9	1.8	3.6	7.4	1.2	2.3	4.7
LC-PUFA ⁴	0.7	3.5	6.3	11.8	2.9	5.0	10.1	3.4	5.6	11.0

735 ¹Includes 14:0, 20:0, 22:0, 24:0.

736 ²Includes 20:1n-9, 20:1n-11, 22:1n-11.

737 ³Includes 18:3n-6.

738 ⁴Includes 20:2n-6, 20:3n-6, 20:4n-6, 22:5n-3.

739

- Formatted: Font: 9 pt, Not Bold
- Formatted: Space Before: 6 pt, After: 0 pt, Line spacing: single
- Formatted: Font: 9 pt, Not Bold
- Formatted: Space After: 0 pt, Line spacing: single
- Formatted: Font: 9 pt, Not Bold
- Formatted: Font: 9 pt, Not Bold
- Formatted: Font: 9 pt, Not Bold
- Formatted: Font: 9 pt, Not Bold
- Formatted: Font: 9 pt, Not Bold
- Formatted: Font: 9 pt, Not Bold
- Formatted: Font: 9 pt, Not Bold
- Formatted: Font: 9 pt, Not Bold

740

741 Table 42. Atlantic salmon primer sequences used for real-time PCR.

Gene	Accession no.	Direction	Primer sequence 5'→3'
<i>ef1a</i>	AF321836	Forward	CACCACCGCCATCTGATCTACAA
		Reverse	TCAGCAGCCTCCTTCTGAACTTC
<i>etif3</i>	DW542195	Forward	CAGGATGTTGTTGCTGGATGGG
		Reverse	ACCCAAGTGGCAGGTCAAGA
<i>rpol2</i>	CA049789	Forward	TAACGCCTGCCTCTTACGTTGA
		Reverse	ATGAGGGACCTTGAGCCAGCAA
<i>aco</i>	DQ364432	Forward	CCTTCATTGTACCTCTCCGCA
		Reverse	CATTTCAACCTCATCAAAGCCAA
$\Delta 5fad$	AF478472	Forward	GCTTGAGCCCGATGGAGG
		Reverse	CAAGATGGAATGCGGAAAATG
$\Delta 6fad_a$	AY458652	Forward	TCCCAGACGTTTGTGTCAGATGC
		Reverse	GCTTTGGATCCCCATTAGTTCCTG
<i>elovl2</i>	TC91192	Forward	CGGGTACAAAATGTGCTGGT
		Reverse	TCTGTTTGCCGATAGCCATT
<i>elovl5b</i>	NM_001136552	Forward	GCAACCTTGACCCAAACAGG
		Reverse	CCTTGTCTCTACGCAAGGGA
<i>srebp1</i>	NM_001195818	Forward	AGCTGCACGGCTTCCAGCAG
		Reverse	TCCTCCGTCTGGCTCCGGG

742

743

Elongation factor 1 alpha (*ef1a*), eukaryotic translation initiation factor 3 (*etif3*), RNA polymerase II polypeptide (*rpol2*), acyl-CoA oxidase (*aco*), $\Delta 5$ desaturase ($\Delta 5fad$), $\Delta 6$ desaturase isoform a ($\Delta 6fad_a$), elongase 2 (*elovl2*), elongase 5b (*elovl5b*), sterol regulatory element binding protein 1 (*srebp1*).

Formatted: Space Before: 6 pt, Line spacing: single

Formatted: Font: (Default) Arial

Formatted: Font: (Default) Arial

744 | Table 23. Fatty acid composition (mol%) in the PL and NL fraction of hepatocytes from Atlantic salmon fed the experimental diets for 26 weeks
 745 | (means ± sem; n = 3)

PL fraction	0%	0.5% EPA	1% EPA	2% EPA	0.5% DHA	1% DHA	2% DHA	0.5% EPA+DHA	1% EPA+DHA	2% EPA+DHA	ANOVA
16:0	18.4 ± 0.29 ^b	19.2 ± 0.28 ^{ab}	19.4 ± 0.07 ^{ab}	19.8 ± 0.53 ^{ab}	19.6 ± 0.21 ^{ab}	20.1 ± 0.51 ^{ab}	20.5 ± 0.41 ^a	20.0 ± 0.21 ^{ab}	20.2 ± 0.35 ^a	19.5 ± 0.18 ^{ab}	0.015
18:0	8.3 ± 0.23	7.6 ± 0.28	7.8 ± 0.32	7.2 ± 0.46	7.1 ± 0.21	7.1 ± 0.14	6.8 ± 0.54	7.4 ± 0.38	7.1 ± 0.44	6.9 ± 0.12	0.150
SFA ¹	29.8 ± 1.70	27.4 ± 0.53	27.7 ± 0.42	27.7 ± 0.92	27.3 ± 0.08	27.6 ± 0.64	27.7 ± 0.15	27.9 ± 0.26	27.9 ± 0.22	27.5 ± 0.85	0.541
18:1n-9	19.1 ± 1.28 ^a	18.9 ± 0.57 ^{ab}	17.0 ± 0.19 ^{abc}	14.8 ± 0.15 ^c	18.3 ± 0.87 ^{ab}	16.8 ± 1.04 ^{abc}	14.7 ± 0.46 ^c	19.4 ± 0.55 ^a	16.4 ± 0.25 ^{abc}	15.7 ± 0.33 ^{bc}	0.0002
MUFA ²	24.2 ± 2.36 ^a	21.4 ± 0.22 ^{ab}	19.0 ± 0.51 ^b	17.0 ± 0.26 ^b	20.4 ± 0.87 ^{ab}	18.5 ± 0.83 ^b	17.0 ± 0.71 ^b	21.4 ± 0.70 ^{ab}	17.8 ± 0.27 ^b	17.7 ± 0.73 ^b	0.0004
18:2n-6	9.9 ± 0.57 ^{ab}	9.7 ± 0.75 ^{ab}	8.7 ± 0.47 ^{ab}	7.2 ± 0.53 ^b	10.8 ± 0.59 ^a	10.1 ± 0.15 ^{ab}	8.8 ± 0.11 ^{ab}	10.6 ± 1.28 ^a	10.0 ± 0.38 ^{ab}	8.1 ± 0.27 ^{ab}	0.007
18:3n-3	0.7 ± 0.04	0.7 ± 0.07	0.7 ± 0.04	0.8 ± 0.12	0.7 ± 0.07	0.7 ± 0.03	0.9 ± 0.05	0.8 ± 0.16	0.8 ± 0.06	0.9 ± 0.06	0.537
20:3n-3	0.04 ± 0.04 ^b	0.12 ± 0.02 ^b	0.14 ± 0.00 ^{ab}	0.20 ± 0.01 ^{ab}	0.14 ± 0.00 ^{ab}	0.15 ± 0.02 ^{ab}	0.40 ± 0.16 ^a	0.14 ± 0.03 ^{ab}	0.18 ± 0.01 ^{ab}	0.23 ± 0.04 ^{ab}	0.02
20:3 n-6	5.9 ± 0.71 ^a	5.5 ± 0.10 ^{ab}	4.0 ± 0.12 ^{bc}	2.0 ± 0.21 ^{de}	5.5 ± 0.27 ^{ab}	3.6 ± 0.24 ^c	1.8 ± 0.20 ^f	5.2 ± 0.29 ^{ab}	3.4 ± 0.24 ^{cd}	1.5 ± 0.09 ^g	<0.0001
20:4n-6	11.9 ± 1.03 ^a	8.7 ± 0.84 ^{ab}	7.2 ± 0.12 ^{bcd}	4.6 ± 0.10 ^d	8.9 ± 0.75 ^{ab}	7.8 ± 0.90 ^{bcd}	5.6 ± 0.50 ^{bcd}	8.6 ± 1.13 ^{abc}	6.8 ± 0.22 ^{bcd}	5.2 ± 0.28 ^{cd}	<0.0001
20:5n-3	1.7 ± 0.07 ^e	4.1 ± 0.09 ^{cd}	5.7 ± 0.38 ^{bc}	9.4 ± 0.30 ^a	1.8 ± 0.21 ^e	2.4 ± 0.39 ^e	2.2 ± 0.23 ^e	2.8 ± 0.12 ^{de}	4.6 ± 0.41 ^{bc}	6.1 ± 0.59 ^b	<0.0001
22:5n-3	2.6 ± 0.68 ^{ab}	1.9 ± 0.18 ^{abc}	2.3 ± 0.07 ^{ab}	2.7 ± 0.12 ^d	0.9 ± 0.13 ^c	0.8 ± 0.09 ^c	0.7 ± 0.09 ^c	1.5 ± 0.09 ^{bc}	1.4 ± 0.03 ^{bc}	1.5 ± 0.11 ^{abc}	<0.0001
22:6n-3	11.2 ± 0.84 ^d	18.5 ± 0.45 ^f	22.8 ± 0.48 ^{de}	26.6 ± 0.41 ^{bc}	21.3 ± 0.83 ^{ef}	26.4 ± 1.21 ^{bcd}	33.3 ± 0.46 ^a	19.2 ± 0.53 ^{ef}	25.5 ± 0.39 ^{cd}	29.2 ± 1.07 ^b	<0.0001
PUFA ³	46.1 ± 2.18 ^b	51.2 ± 0.65 ^a	53.3 ± 0.64 ^a	55.3 ± 0.89 ^a	52.3 ± 0.83 ^a	53.9 ± 0.49 ^a	55.4 ± 0.56 ^a	50.7 ± 0.93 ^b	54.3 ± 0.34 ^a	54.7 ± 0.54 ^a	<0.0001
n-6 PUFA	24.0 ± 1.40^b	20.5 ± 0.16^{bcd}	17.8 ± 0.41^{def}	13.9 ± 0.51^g	22.0 ± 0.41^{ab}	19.9 ± 0.55^{bcd}	16.4 ± 0.47^{efg}	21.3 ± 0.37^{abc}	18.6 ± 0.26^{cde}	15.6 ± 0.09^{fg}	<0.0001
n-6/n-3	1.5 ± 0.08 ^a	0.8 ± 0.01 ^{bc}	0.6 ± 0.01 ^{def}	0.4 ± 0.01 ^g	0.9 ± 0.03 ^b	0.7 ± 0.03 ^{cd}	0.4 ± 0.01 ^{efg}	0.9 ± 0.02 ^b	0.6 ± 0.02 ^{de}	0.4 ± 0.01 ^{fg}	<0.0001
n-6 DI ⁴	0.64 ± 0.01 ^a	0.59 ± 0.03 ^{ab}	0.57 ± 0.01 ^{abcd}	0.48 ± 0.03 ^{cd}	0.57 ± 0.02 ^{abc}	0.53 ± 0.02 ^{abcd}	0.46 ± 0.01 ^d	0.57 ± 0.05 ^{abcd}	0.50 ± 0.02 ^{bcd}	0.46 ± 0.01 ^d	0.0001
NL fraction											
16:0	17.9 ± 4.75	13.5 ± 1.05	15.3 ± 1.01	13.0 ± 0.50	14.7 ± 1.17	14.5 ± 1.44	16.2 ± 0.79	14.4 ± 0.46	19.3 ± 0.70	17.3 ± 0.65	0.267
18:0	11.1 ± 2.67	9.9 ± 0.32	10.0 ± 0.25	9.1 ± 0.77	8.1 ± 0.29	9.1 ± 0.93	9.9 ± 1.48	10.0 ± 0.38	8.4 ± 1.01	8.6 ± 0.10	0.715
SFA ¹	31.5 ± 8.03	24.4 ± 0.81	26.0 ± 1.02	22.7 ± 1.33	23.8 ± 1.01	24.5 ± 1.91	26.7 ± 1.55	26.3 ± 1.39	28.3 ± 0.17	26.7 ± 0.85	0.604
18:1n-9	41.8 ± 5.43	35.2 ± 5.58	33.0 ± 1.85	30.5 ± 6.96	35.0 ± 1.86	33.6 ± 3.17	26.3 ± 0.92	35.8 ± 3.74	27.1 ± 3.70	21.2 ± 1.29	0.068
MUFA ²	46.6 ± 6.63	39.9 ± 6.26	37.6 ± 2.39	35.3 ± 8.33	39.3 ± 2.38	37.0 ± 3.00	29.6 ± 0.80	40.9 ± 5.11	30.0 ± 4.10	24.1 ± 1.41	0.101
18:2n-6	10.1 ± 0.58	10.1 ± 0.47	11.0 ± 0.83	10.2 ± 0.42	11.7 ± 0.38	12.8 ± 0.50	12.4 ± 0.56	11.1 ± 1.44	12.3 ± 0.94	10.2 ± 0.96	0.122
18:3n-3	0.7 ± 0.39	0.9 ± 0.06	1.2 ± 0.09	1.3 ± 0.09	1.0 ± 0.07	1.3 ± 0.17	1.6 ± 0.22	1.0 ± 0.14	1.5 ± 0.23	1.3 ± 0.16	0.097
20:3n-3	nd	nd	0.10 ± 0.05	0.27 ± 0.01	0.09 ± 0.05	0.07 ± 0.07	0.10 ± 0.10	0.14 ± 0.07	0.06 ± 0.06	0.22 ± 0.11	
20:3n-6	1.9 ± 0.93 ^b	3.4 ± 0.53 ^a	2.5 ± 0.17 ^{ab}	1.5 ± 0.10 ^b	3.6 ± 0.32 ^a	2.4 ± 0.23 ^{ab}	1.5 ± 0.17 ^b	3.2 ± 0.56 ^a	2.5 ± 0.35 ^{ab}	1.5 ± 0.08 ^b	0.010
20:4n-6	2.7 ± 0.20	5.9 ± 1.09	4.4 ± 0.77	4.4 ± 1.45	5.8 ± 0.49	4.9 ± 0.98	4.6 ± 0.21	4.8 ± 1.18	4.6 ± 1.26	5.3 ± 0.24	0.487
20:5n-3	0.6 ± 0.33 ^c	2.3 ± 0.63 ^{bc}	3.7 ± 0.37 ^{ab}	5.7 ± 1.15 ^a	1.2 ± 0.30 ^{bc}	1.6 ± 0.21 ^{bc}	1.8 ± 0.28 ^{bc}	1.4 ± 0.34 ^{bc}	3.7 ± 0.64 ^{ab}	5.2 ± 0.58 ^a	<0.0001
22:5n-3	0.1 ± 0.11 ^c	1.1 ± 0.21 ^{abc}	1.4 ± 0.09 ^{ab}	2.0 ± 0.34 ^a	0.6 ± 0.11 ^{bc}	0.4 ± 0.18 ^{bc}	0.6 ± 0.09 ^{bc}	0.7 ± 0.20 ^{bc}	0.8 ± 0.40 ^{bc}	1.4 ± 0.09 ^{ab}	<0.0001
22:6n-3	4.2 ± 1.49 ^c	9.8 ± 2.93 ^{abc}	10.1 ± 1.54 ^{abc}	14.4 ± 4.24 ^{abc}	10.3 ± 0.60 ^{abc}	12.5 ± 2.79 ^{abc}	18.9 ± 1.65 ^a	8.0 ± 2.59 ^{bc}	14.1 ± 3.37 ^{abc}	22.0 ± 2.88 ^a	0.005

Formatted ... [1]

Formatted ... [2]

Formatted ... [3]

Formatted ... [4]

Formatted ... [5]

Formatted ... [6]

Formatted ... [7]

Formatted ... [8]

Formatted ... [9]

Formatted ... [10]

Formatted ... [11]

Formatted ... [12]

Formatted ... [13]

Formatted ... [14]

Formatted ... [15]

Formatted ... [16]

Formatted ... [17]

Formatted ... [18]

Formatted ... [19]

Formatted ... [20]

Formatted ... [21]

Formatted ... [22]

Formatted ... [23]

Formatted ... [24]

Formatted ... [25]

Formatted ... [26]

Formatted ... [27]

Formatted ... [28]

Formatted ... [29]

Formatted ... [30]

PUFA ³	21.9 ± 2.03 ^b	35.7 ± 5.59 ^{ab}	36.4 ± 3.34 ^{ab}	42.0 ± 7.06 ^{ab}	36.9 ± 1.37 ^{ab}	38.5 ± 3.17 ^{ab}	43.7 ± 1.20 ^a	32.8 ± 6.50 ^{ab}	41.7 ± 4.26 ^{ab}	49.2 ± 1.95 ^a	0.017
n-6 PUFA	14.4 ± 1.41	18.3 ± 1.28	17.6 ± 1.40	17.2 ± 1.32	20.1 ± 0.29	20.4 ± 0.54	19.3 ± 0.39	18.4 ± 2.67	19.1 ± 0.28	17.9 ± 0.54	0.12
n-6/n-3	2.9 ± 0.82 ^a	1.4 ± 0.24 ^{ab}	1.1 ± 0.04 ^b	0.8 ± 0.19 ^b	1.5 ± 0.09 ^{ab}	1.3 ± 0.16 ^{ab}	0.8 ± 0.05 ^b	1.9 ± 0.45 ^{ab}	1.0 ± 0.17 ^b	0.6 ± 0.06 ^b	0.004
n-6 DI ⁴	0.30 ± 0.04	0.47 ± 0.04	0.38 ± 0.02	0.36 ± 0.07	0.44 ± 0.03	0.36 ± 0.04	0.33 ± 0.02	0.41 ± 0.03	0.36 ± 0.07	0.40 ± 0.03	0.25

746 Mean values within a row with unlike superscript letters were significantly different ($P < 0.05$) by ANOVA followed by Tukey's honestly significant difference *post hoc* test. nd,
 747 not detectable levels.

748 ¹Includes 14:0 and 20:0

749 ²Includes 16:1 n-7 and 20:1 n-9

750 ³Includes 18:3 n-6 and 20:2 n-6

751 ⁴n-6 DI = (20:3 n-6 + 20:4 n-6) / (18:2 n-6 + 20:3 n-6 + 20:4 n-6)

For Peer Review

- Formatted ... [32]
- Formatted ... [33]
- Formatted ... [34]
- Formatted ... [35]
- Formatted Table ... [31]
- Formatted ... [36]
- Formatted ... [37]
- Formatted ... [38]
- Formatted ... [39]
- Formatted ... [40]
- Formatted ... [41]
- Formatted ... [42]
- Formatted ... [43]
- Formatted ... [44]
- Formatted ... [45]
- Formatted ... [46]
- Formatted ... [47]
- Formatted ... [48]
- Formatted ... [49]
- Formatted ... [50]
- Formatted ... [51]
- Formatted ... [52]
- Formatted ... [53]
- Formatted ... [54]
- Formatted ... [55]
- Formatted ... [56]
- Formatted ... [57]
- Formatted ... [58]
- Formatted ... [59]
- Formatted ... [60]
- Formatted ... [61]

752 Table 34. Fate of radioactivity from [1-¹⁴C] 18:3n-3 incubated in Atlantic salmon hepatocytes in the presence or absence of lipoic acid isolated
 753 from fish fed 10 experimental diets containing different levels of EPA and/or DHA for 26 weeks. Values are means ± sem (n = 3).

	Cellular lipids (nmol)		Secreted lipids in media (nmol)		CO ₂ in medium (nmol)		ASPF in medium (nmol)		Recovery (%)	
	CONT	LA	CONT	LA	CONT	LA	CONT	LA	CONT	LA
0 %	13.9 ± 0.3	13.5 ± 0.4	2.40 ± 0.12	2.56 ± 0.12	0.021 ± 0.003	0.014 ± 0.002	0.56 ± 0.02	0.56 ± 0.04	80.5 ± 1.0	79.4 ± 2.8
0.5% EPA	12.6 ± 0.3	12.2 ± 0.3	2.60 ± 0.12	2.78 ± 0.08	0.013 ± 0.001	0.008 ± 0.001	0.49 ± 0.03	0.54 ± 0.07	74.8 ± 1.4	73.9 ± 2.0
1.0% EPA	12.1 ± 0.5	12.0 ± 0.4	3.36 ± 0.06	3.40 ± 0.17	0.017 ± 0.002	0.010 ± 0.001	0.56 ± 0.06	0.93 ± 0.24	76.4 ± 2.3	78.0 ± 1.7
2.0% EPA	13.4 ± 1.0	13.7 ± 0.7	2.47 ± 0.27	2.90 ± 0.59	0.016 ± 0.003	0.015 ± 0.003	0.52 ± 0.05	0.63 ± 0.08	78.0 ± 3.5	81.9 ± 0.4
0.5% DHA	12.1 ± 0.9	12.6 ± 0.4	2.87 ± 0.57	2.91 ± 0.70	0.019 ± 0.001	0.013 ± 0.001	0.57 ± 0.05	0.73 ± 0.12	74.1 ± 2.1	77.3 ± 2.2
1.0% DHA	11.2 ± 0.5	10.9 ± 0.5	4.12 ± 0.48	4.06 ± 0.15	0.018 ± 0.001	0.012 ± 0.001	0.62 ± 0.03	0.78 ± 0.06	76.2 ± 1.2	75.1 ± 3.2
2.0% DHA	12.4 ± 1.1	12.0 ± 0.8	3.31 ± 0.42	3.82 ± 0.19	0.021 ± 0.003	0.016 ± 0.003	0.63 ± 0.04	0.87 ± 0.07	78.0 ± 5.5	79.4 ± 4.4
0.5% EPA+DHA	13.1 ± 1.3	13.4 ± 0.2	2.19 ± 0.30	2.14 ± 0.30	0.038 ± 0.023	0.011 ± 0.000	0.51 ± 0.03	0.56 ± 0.09	75.6 ± 4.8	76.7 ± 2.7
1.0% EPA+DHA	11.4 ± 1.1	11.4 ± 0.7	3.52 ± 0.45	3.55 ± 0.53	0.019 ± 0.002	0.015 ± 0.001	0.61 ± 0.03	0.74 ± 0.06	74.1 ± 3.8	74.6 ± 1.0
2.0% EPA+DHA	12.6 ± 0.8	12.0 ± 1.0	3.43 ± 0.55	3.74 ± 0.57	0.017 ± 0.001	0.020 ± 0.004	0.58 ± 0.01	0.80 ± 0.02	79.2 ± 1.7	79.0 ± 2.4
<i>P</i> _{Diet}	0.013		0.0002		0.58		0.02		0.32	
ANOVA <i>P</i> _{LA}	0.69		0.36		0.01		< 0.0001		0.52	
<i>P</i> _{Diet x LA}	0.99		0.99		0.47		0.47		0.99	

754 Values are means ± sem (n = 3). -ASPF, acid-soluble products fraction. CONT, control cells; LA, cells supplemented with lipoic acid.

755 Equal amount of cells was seeded for each experimental condition, corresponding to 5.6 ± 0.25 mg protein per flask (mean ± SEM).

756

757 | Table 45. Percentage distribution between phospholipids (PL), mono- and diacylglycerol (MDG), triglycerides (TAG), and cholesterol esters
 758 | (CE) produced from [1-¹⁴C] 18:3n-3 in Atlantic salmon hepatocytes in the presence or absence of lipoic acid from fish fed different levels of EPA
 759 | and/or DHA for 26 weeks prior to the experiment (means ± sem; n = 3)

	PL (%)		MDG (%)		TAG (%)		CE (%)	
	CONTR OL	LA	CONTR OL	LA	CONTR OL	LA	CONTR OL	LA
0 %	90.9 ± 0.9	86.8 ± 0.7	1.3 ± 0.6	1.5 ± 0.4	7.5 ± 0.9	11.5 ± 0.5	0.3 ± 0.0	0.1 ± 0.1
0.5% EPA	89.2 ± 1.8	80.2 ± 1.9	0.5 ± 0.3	1.9 ± 0.2	10.2 ± 1.9	17.7 ± 1.9	nd	0.2 ± 0.2
1.0% EPA	87.7 ± 0.5	75.4 ± 2.4	2.0 ± 0.3	3.0 ± 0.8	10.2 ± 0.3	21.2 ± 1.6	0.1 ± 0.1	0.4 ± 0.1
2.0% EPA	74.8 ± 4.1	63.7 ± 1.5	1.4 ± 0.3	3.2 ± 1.1	23.5 ± 3.7	32.2 ± 1.0	0.4 ± 0.1	0.9 ± 0.2
0.5% DHA	89.8 ± 2.4	81.3 ± 1.5	1.3 ± 0.1	2.3 ± 0.1	8.8 ± 2.3	15.8 ± 1.4	0.1 ± 0.1	0.6 ± 0.0
1.0% DHA	88.6 ± 2.5	75.3 ± 0.6	2.7 ± 0.7	3.5 ± 0.6	8.4 ± 1.8	20.6 ± 1.1	0.2 ± 0.1	0.6 ± 0.3
2.0% DHA	84.3 ± 0.9	74.7 ± 2.1	1.8 ± 0.2	2.9 ± 0.3	13.6 ± 0.6	21.7 ± 1.8	0.4 ± 0.2	0.8 ± 0.1
0.5% EPA+DHA	84.0 ± 6.3	77.1 ± 6.7	1.6 ± 0.9	2.0 ± 1.2	14.2 ± 5.3	20.3 ± 5.6	0.1 ± 0.1	0.6 ± 0.0
1.0% EPA+DHA	87.5 ± 2.0	77.0 ± 2.8	2.4 ± 1.0	2.7 ± 0.8	10.0 ± 2.6	19.6 ± 2.1	0.1 ± 0.0	0.8 ± 0.2
2.0% EPA+DHA	80.3 ± 2.8	69.9 ± 1.9	2.7 ± 1.4	3.6 ± 1.2	16.7 ± 2.8	25.6 ± 3.4	0.3 ± 0.1	0.9 ± 0.3
<i>P</i> _{Diet}	< 0.0001		0.14		< 0.0001			
ANOVA <i>P</i> _{LA}	< 0.0001		0.009		< 0.0001			
<i>P</i> _{Diet x LA}	0.91		0.99		0.91			

760 | Total radioactivity recovered in the different lipid classes was set to 100% for each dietary group (PL+ MDG + TAG + CE = 100%). The different *P*-values are significance levels
 761 | from two-way ANOVA. nd = non detectable amounts; CONT = control cells; LA = cells supplemented with lipoic acid.

762

763 | Table 56. Percentage of substrate added recovered in PUFA from the phospholipid fraction of hepatocytes incubated with [1-¹⁴C] 18:3n-3 in
 764 | lipoic acid free or supplemented media (means ± sem; n = 3). The fish had been fed diets containing different levels of EPA and/or DHA for 26
 765 | weeks prior to the experiment.

	18:3n-3		18:4n-3		20:3n-3		20:4n-3		20:5n-3		22:5n-3		22:6n-3	
	CONT	LA	CONT	LA	CONT	LA	CONT	LA	CONT	LA	CONT	LA	CONT	LA
0%	36.4 ± 0.9	30.1 ± 0.7	1.0 ± 0.13	1.4 ± 0.12	0.5 ± 0.03	2.6 ± 0.4	5.4 ± 0.33	4.4 ± 0.29	10.2 ± 0.5	6.8 ± 0.4	1.0 ± 0.08	1.1 ± 0.20	5.3 ± 0.5	8.2 ± 1.1
0.5% EPA	28.6 ± 1.2	21.9 ± 2.0	0.8 ± 0.09	0.9 ± 0.23	0.6 ± 0.28	3.7 ± 0.71	3.5 ± 0.62	2.5 ± 0.32	12.7 ± 0.5	7.4 ± 0.7	0.9 ± 0.11	0.8 ± 0.18	6.0 ± 0.7	8.4 ± 0.6
1.0% EPA	26.6 ± 0.9	22.1 ± 0.1	0.6 ± 0.19	0.5 ± 0.17	1.8 ± 0.47	4.7 ± 0.59	2.3 ± 0.83	1.5 ± 0.55	10.8 ± 2.0	6.4 ± 1.7	0.6 ± 0.11	0.4 ± 0.13	7.3 ± 0.1	7.0 ± 0.6
2.0% EPA	23.8 ± 1.4	19.6 ± 1.4	0.4 ± 0.10	0.4 ± 0.06	3.8 ± 1.11	8.3 ± 1.42	1.7 ± 0.30	1.0 ± 0.14	8.0 ± 1.3	3.9 ± 0.6	0.5 ± 0.06	0.2 ± 0.04	8.0 ± 0.1	6.4 ± 1.0
0.5% DHA	27.6 ± 1.1	24.3 ± 0.8	0.7 ± 0.27	0.7 ± 0.27	1.2 ± 0.33	4.5 ± 0.71	3.1 ± 0.96	2.0 ± 0.50	10.4 ± 2.4	6.4 ± 1.3	1.0 ± 0.27	0.7 ± 0.18	7.0 ± 0.4	8.3 ± 1.4
1.0% DHA	26.2 ± 1.0	22.0 ± 1.0	0.5 ± 0.03	0.4 ± 0.09	2.1 ± 0.24	2.6 ± 1.08	1.4 ± 0.12	1.0 ± 0.09	9.4 ± 1.4	7.3 ± 1.6	0.3 ± 0.05	0.1 ± 0.09	6.9 ± 0.7	5.3 ± 0.6
2.0% DHA	26.6 ± 3.0	22.2 ± 1.8	0.4 ± 0.05	0.3 ± 0.04	5.0 ± 0.95	8.5 ± 1.84	1.3 ± 0.30	0.7 ± 0.06	5.7 ± 0.9	3.3 ± 0.5	0.2 ± 0.19	0.1 ± 0.07	8.7 ± 0.5	5.7 ± 0.4
0.5% E+D	27.3 ± 1.5	22.2 ± 2.9	1.1 ± 0.42	1.3 ± 0.31	0.7 ± 0.33	3.7 ± 1.42	4.1 ± 0.62	3.1 ± 0.40	11.0 ± 0.4	6.6 ± 0.5	1.1 ± 0.20	0.7 ± 0.15	6.0 ± 1.2	10.0 ± 1.9
1.0% E+D	27.1 ± 0.0	21.5 ± 1.3	0.5 ± 0.00	0.4 ± 0.09	2.3 ± 0.00	5.9 ± 1.62	2.0 ± 0.00	1.1 ± 0.04	8.4 ± 0.0	4.6 ± 0.9	0.7 ± 0.00	0.4 ± 0.11	7.9 ± 0.0	6.9 ± 1.0
2.0% E+D	25.1 ± 2.7	20.6 ± 2.6	0.4 ± 0.06	0.3 ± 0.04	4.7 ± 0.38	8.5 ± 0.35	1.5 ± 0.26	0.8 ± 0.13	6.9 ± 1.1	3.5 ± 0.7	0.3 ± 0.10	0.1 ± 0.02	8.8 ± 1.3	5.6 ± 0.7
ANOVA	<i>P</i> _{Diet}	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001	0.0003	< 0.0001	< 0.0001	< 0.0001	< 0.0001	0.75
	<i>P</i> _{LA}	< 0.0001	< 0.0001	0.81	0.81	< 0.0001	< 0.0001	0.0002	0.0002	< 0.0001	< 0.0001	0.01	0.01	0.97
	<i>P</i> _{Diet x LA}	0.99	0.99	0.95	0.95	0.69	0.69	0.99	0.99	0.96	0.96	0.85	0.85	0.0016

766 | Minor amounts of radioactivity (0.48 ± 0.04%; mean ± sem) were recovered in two non-identified peaks. [CONT, control cells; LA, cells supplemented with lipoic acid.](#)

767

768 | Table 67. Percentage of substrate added recovered in PUFA from the neutral lipid fraction of hepatocytes incubated with [1-¹⁴C] 18:3n-3 in lipoic
 769 acid free or supplemented media (means ± sem; n = 3). The fish had been fed diets containing different levels of EPA and/or DHA for 26 weeks
 770 prior to the experiment.

	18:3n-3		18:4n-3		20:3n-3		20:4n-3		20:5n-3		22:5n-3		22:6n-3	
	CONT	LA	CONT	LA	CONT	LA	CONT	LA	CONT	LA	CONT	LA	CONT	LA
0%	3.6 ± 0.5	4.5 ± 0.5	0.5 ± 0.03	0.3 ± 0.07	0.1 ± 0.06	1.6 ± 0.1	0.14 ± 0.14	0.26 ± 0.02	0.58 ± 0.11	0.53 ± 0.20	nd	nd	0.77 ± 0.18	1.10 ± 0.11
0.5% EPA	3.1 ± 0.8	5.6 ± 0.6	0.7 ± 0.32	0.8 ± 0.16	0.5 ± 0.24	2.8 ± 0.50	0.11 ± 0.11	0.14 ± 0.09	0.86 ± 0.21	0.49 ± 0.04	0.10 ± 0.06	0.02 ± 0.02	0.82 ± 0.05	1.46 ± 0.14
1.0% EPA	3.5 ± 0.2	6.6 ± 0.8	0.4 ± 0.08	0.5 ± 0.08	1.0 ± 0.10	3.8 ± 0.32	0.06 ± 0.06	0.04 ± 0.04	0.70 ± 0.14	0.69 ± 0.10	nd	nd	1.15 ± 0.15	2.25 ± 0.22
2.0% EPA	8.6 ± 2.0	11.4 ± 0.6	0.5 ± 0.05	0.6 ± 0.03	3.5 ± 1.20	7.8 ± 1.23	0.10 ± 0.05	0.21 ± 0.16	0.83 ± 0.06	0.57 ± 0.13	0.03 ± 0.03	nd	2.08 ± 0.41	2.76 ± 0.13
0.5% DHA	3.3 ± 0.9	5.5 ± 0.6	0.4 ± 0.12	0.4 ± 0.09	0.4 ± 0.22	2.6 ± 0.44	0.06 ± 0.06	0.14 ± 0.10	0.43 ± 0.17	0.51 ± 0.17	nd	nd	0.86 ± 0.20	1.73 ± 0.19
1.0% DHA	3.5 ± 0.6	6.2 ± 0.7	0.3 ± 0.13	0.5 ± 0.10	0.7 ± 0.45	2.6 ± 0.28	0.04 ± 0.04	0.04 ± 0.04	0.61 ± 0.15	1.16 ± 0.23	nd	nd	1.14 ± 0.44	2.40 ± 0.17
2.0% DHA	4.8 ± 0.2	6.4 ± 0.3	0.3 ± 0.06	0.3 ± 0.07	2.2 ± 0.13	5.1 ± 0.39	nd	0.03 ± 0.03	0.31 ± 0.03	0.34 ± 0.18	nd	nd	1.55 ± 0.18	1.95 ± 0.44
0.5% E+D	5.0 ± 2.2	7.5 ± 2.0	1.4 ± 0.93	1.0 ± 0.67	1.0 ± 0.31	2.9 ± 0.24	0.48 ± 0.48	0.30 ± 0.30	1.05 ± 0.58	0.50 ± 0.27	nd	nd	1.13 ± 0.28	1.61 ± 0.34
1.0% E+D	3.5 ± 0.0	5.9 ± 0.8	0.3 ± 0.00	0.5 ± 0.11	1.2 ± 0.00	3.9 ± 0.77	nd	nd	0.56 ± 0.00	0.36 ± 0.18	nd	nd	1.15 ± 0.00	1.64 ± 0.34
2.0% E+D	6.3 ± 0.7	8.1 ± 0.1	0.4 ± 0.08	0.3 ± 0.09	2.4 ± 0.35	5.8 ± 0.22	0.08 ± 0.08	0.17 ± 0.10	0.75 ± 0.08	0.40 ± 0.11	0.04 ± 0.04	0.07 ± 0.07	1.66 ± 0.17	2.28 ± 0.06
ANOVA	<i>P</i> _{Diet}		0.08		< 0.0001				0.20				< 0.0001	
	<i>P</i> _{LA}		0.91		< 0.0001				0.20				< 0.0001	
	<i>P</i> _{Diet x LA}		0.99		0.34				0.31				0.65	

771 | Minor amounts of radioactivity (0.12 ± 0.02%; mean ± sem) were recovered in two non-identified peaks. nd = non detectable amounts; CONT = control cells; LA = cells
 772 supplemented with lipoic acid.

773

774 | Table 78. Spearman's correlation coefficients between cellular EPA or cellular DHA and 18:3n-3 and its FA products in control hepatocytes and
775 | hepatocytes supplemented with lipoic acid.

	Cellular EPA		Cellular DHA	
	CONT	LA	CONT	LA
18:3n-3	-0.325 (0.091)	-0.443 (0.014)	-0.519 (0.005)	-0.392 (0.032)
18:4n-3	-0.257 (0.187)	-0.310 (0.096)	-0.663 (0.0001)	-0.754 (< 0.0001)
20:3n-3	0.393 (0.039)	0.454 (0.012)	0.883 (< 0.0001)	0.582 (0.0007)
20:4n-3	-0.284 (0.144)	-0.322 (0.082)	-0.763 (< 0.0001)	-0.820 (< 0.0001)
20:5n-3	-0.085 (0.668)	-0.291 (0.119)	-0.6842 (< 0.0001)	-0.589 (0.0006)
22:5n-3	-0.275 (0.157)	-0.306 (0.100)	-0.775 (< 0.0001)	-0.854 (<0.0001)
22:6n-3	0.390 (0.040)	-0.201 (0.287)	0.767 (< 0.0001)	

776 | CONT, control cells; LA, cells supplemented with lipoic acid.

Formatted: Space Before: 6 pt

01:00 PM

01:00 PM

01:00 PM

01:00 PM

01:00 PM

01:00 PM

01:00 PM

01:00 PM

01:00 PM

01:00 PM

For Peer Review

01:00 PM

01:00 PM

01:00 PM

01:00 PM

01:00 PM

01:00 PM

01:00 PM

01:00 PM

01:00 PM

For Peer Review

07:00 PM

07:00 PM

07:00 PM

07:00 PM

07:00 PM

07:00 PM

07:00 PM

07:00 PM

07:00 PM

07:00 PM

For Peer Review

07:00 PM

07:00 PM

07:00 PM

07:00 PM

07:00 PM

07:00 PM

07:00 PM

07:00 PM

07:00 PM

For Peer Review

For Peer Review





Fig.2







Fig.4



	P_{Diet}	P_{LA}	$P_{\text{Diet} \times \text{LA}}$
<i>aco</i>	0.03	0.85	0.62
<i>Δ5fad</i>	0.02	0.11	0.59
<i>Δ6fad_a</i>	< 0.0001	0.72	0.98
<i>elov2</i>	< 0.0001	0.005	0.47
<i>elov5b</i>	0.03	0.0006	0.72
<i>srebp1</i>	0.004	0.97	0.21

